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ABSTRACT
Development of a Pediatric Model of NAFLD In Neonatal Iberian Pigs
Gabriella Veronica Hernandez

The prevalence of non-alcoholic fatty liver disease (NAFLD) in children has
increased over the past decades, creating a need for animal models that recapitulate the
features of the pediatric disease. Iberian pigs have a leptin-resistant phenotype
characterized by hyperleptinemia, hyperphagia, and extreme adipogenesis. We
hypothesized that neonatal Iberian pigs fed a high fat high-fructose (HFF) diet will
develop a pattern of liver injury resembling pediatric NAFLD. In addition, we sought to
determine if a mixture of probiotics would prevent the disease. Animals were fed 1 of 4
diets containing (g/kg body weight × d) 0 g fructose, 11 g fat and 199 kcal (CON-N;
n=8), 22 g fructose, 16 g fat and 300 kcal (HFF2-N; n=8), CON + probiotic (CON-P;
n=6), or HFF2 + probiotic (HFF2-P; n=6) every 6 h for 70 d. The probiotic mixture (6.2
× 104 cfu/mL) contained Pediococcus acidilactici, Pediococcus pentosaceus,
Lactobacillus plantarum and Bacillus amyloliquefaciens. Body weight was recorded
every 3 d. Serum markers of liver injury and dyslipidemia were measured on d 40 and 65
at 2 h post feeding. Fasting leptin, insulin, glucose and homeostatic model assessment
(HOMA) values were assessed on d 70. Liver and skeletal muscle (longissimus dorsi)
were collected on d 70 for histology, triacylglyceride (TAG) quantification, relative gene
expression, and Western blot analysis. Metabolomic analysis was performed on liver
tissue and plasma. Body weight was not significantly greater in HFF fed pigs compared
to CON. Leptin, alanine and aspartate aminotransferases, alkaline phosphatase, lactate
iv

dehydrogenase and total bilirubin were increased (P ≤ 0.001), and high and low density
lipoproteins decreased (P ≤ 0.05) in HFF2-N and HFF2-P. Livers in HFF2-P and HFF2N had higher relative weight and TAG (P ≤ 0.001), micro and macrovesicular steatosis,
ballooning degeneration, Mallory-denk bodies, inflammation and necrosis, increased
gene expression of TNFα, TGFβ, IL1α and PPARγ (P ≤ 0.001), and decreased ChREBP
(P ≤ 0.001). A probiotic affect was seen as pigs fed CON-P and HFF2-P had higher
insulin and HOMA values were increased (P ≤ 0.05). Western blot analysis showed
dysregulation of autophagy in liver of pigs fed CON-P and HFF2-P, and in skeletal
muscle of pigs fed CON-N and HFF2-N. Metabolomic analysis demonstrated
dysregulation of one-carbon metabolism, the tricarboxylic acid cycle (TCA), the urea
cycle, and amino acid metabolism of pigs fed HFF2 diets compared to CON diets. In
conclusion, Iberian pigs fed a HFF diet recapitulate many pediatric NAFLD-associated
features, in the absence of obesity and independently of probiotic supplementation,
suggesting a potentially suitable model for pediatric NAFLD research. Furthermore,
probiotic supplementation did not ameliorate the onset of NAFLD when fed in
conjunction with a HFF diet.

Keywords: NAFLD, Model, Pediatric, Iberian Pig, Probiotics
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1. INTRODUCTION
1.1 Prevalence of NAFLD in children
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common
cause of chronic liver disease worldwide (Kumar & Mohan, 2017). NAFLD is a
progressive disease that ranges from simple steatosis to non-alcoholic steatohepatitis
(NASH) and cirrhosis without the excessive consumption of alcohol. Currently, the vast
majority of research has focused in adults; however, NAFLD affects 3-10% of children
worldwide (Giorgio et al., 2013). In the United States, NAFLD prevalence is estimated to
be 0.7% in 2-4 years old infants to 17.3% in adolescents, and up to 38% among those
with obesity (Schwimmer et al., 2006). Alarmingly, these numbers may underestimate
the effected number of children affected, as NAFLD is often asymptomatic in pediatric
populations (Berardis and Sokal, 2014). In addition, those who are not diagnosed are at
risk of developing cirrhosis and ultimately end-stage liver disease, as well as increase
their risk of developing other diseases such as cardiovascular disease and atherosclerosis
(Patil and Sood, 2017; Sung et al., 2009).
1.2 Pathogenesis and risk factors of NAFLD
Typically NAFLD is thought to occur as a two-hit model, with the ‘first hit’ being
steatosis,

and

the

‘second

hits’

being

liver

injury

such

as

inflammatory

cytokines/adipokines, mitochondrial dysfunction, and oxidative stress, which ultimately
leads to NASH and fibrosis (Dowman et al., 2010). However, many studies have
suggested a multi-hit model that does not occur in a linear fashion, but is a result of
complex interactions between several metabolic processes (Polyzos et al., 2009).
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Additionally, other metabolic disorders such as obesity, diabetes, hyperdyslipemia, and
insulin resistance, have been linked to pediatric NAFLD (Marchesini et al., 2003).
However, it remains unclear if metabolic syndrome is necessary for the development of
NAFLD, or simply a related consequence of a diet high in carbohydrates and high in fats
(Western diet). It is important to note that lean NAFLD can occur in patients, and is often
more prevalent in younger patients (Wattacheril and Sanyal, 2016). It is known that diet
plays a critical role in the pathogenesis of the disease. Previous studies have found an
association Western diet and the prevalence of pediatric NAFLD, which has led to much
interest in the roles of fat and sugar (Solga et al., 2004). Specifically, fructose has
emerged as a key mediator in NAFLD. As the liver is the primary site for fructose
metabolism, fructose has been implicated to play a critical role in the pathogenesis of
NAFLD, and is thought to drive the progression of the disease into NASH through the
formation of reactive oxygen species, the dysregulation of the insulin signaling pathway,
and elevation in the rate of de novo lipogenesis (Lim et al., 2010). Furthermore, fat
sources with high amounts of saturated fatty acids are thought to exacerbate the disease
by promoting cellular dysfunction and endoplasmic reticulum stress (Leamy et al., 2014).
Finally, cholesterol has been shown to increase levels of steatosis in the liver, although
the mechanisms are less clear (Tu et al., 2016). For these reasons, this study utilized these
nutrients to ensure the development of NAFLD.
Despite the association between the Western diet and NAFLD, there molecular
mechanisms involved in the pathogenesis of NAFLD are still not fully understood.
Metabolomic profiling has identified choline metabolism as key mediator of the
progression of NAFLD, due to its involvement in lipid metabolism, methylation-
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dependent biosynthesis of molecules, and mitochondrial bioenergetics (Corbin and
Zeisel, 2012). In fact, the use of choline-deficient diets have often been used in order to
induce NAFLD and increase the rate of progression (Corbin and Zeisel, 2012).
Nevertheless further insight and analysis on choline and other metabolites is needed to
deepen the understanding of the mechanistic driving forces of NAFLD.
1.3 Overview of current models of pediatric NAFLD
While many rodent models of NAFLD/NASH exist, few focus on the
pathogenesis of diet-induced NAFLD in children, likely due to the speed at which mice
reach sexual maturity. However, a study conducted in 21 day-old mice found that after
feeding mice a high-fat diet for 6 consecutive weeks, mice had increased hepatic lipid
accumulation (Chen et al., 2015). Additionally, a rabbit model of pediatric NAFLD
exists, where rabbits aged 4-6 weeks old were fed a high-fat diet with cholesterol
supplementation for 8 and 12 weeks, resulting in hepatic steatosis, inflammation,
ballooning, and fibrosis (Fu et al., 2009). While these studies successfully developed
models that recapitulated the onset of NAFLD and even the progression to NASH, it is
important to consider the anatomical and physiological differences between these animals
and humans. Pigs provide a more accurate translational model to humans; however, to
date pediatric models of NAFLD in swine are sparse. In the past 10 years there have been
several models of NAFLD/NASH in multiple swine breeds such as Ossabaw swine,
Göttingen minipigs, Bama minipigs, and Iberian pigs (Table 1.1); however, these models
focus on the adult pathogenesis of NAFLD (Liang et al., 2015; Schumacher‑Petersen et
al., 2019; Torres-Rovira et al., 2011; Xia et al., 2014;). Currently, a model of diet-induced
NASH exists in juvenile Ossabaw swine, which was aimed to discover the effects of a
3

Western diet in juvenile populations. In this study 5 week old, female Ossabaw swine
were given ad libitum access to a high-fat, high-fructose, high-cholesterol diet for 16 and
36 weeks, resulting in hepatic steatosis, hepatocyte ballooning, inflammation, and fibrosis
(Panasevich et al., 2017). While this study provided relevant insight in to the
pathogenesis of juvenile NAFLD, the starting age of the swine and the length of the study
resulted in a study population that was no longer truly pediatric, since swine reach sexual
maturity between 4 and 6 months (Smith and Swindle, 2006). An additional caveat in
published models of NAFLD is found in the diet formulation and feeding protocols. The
majority of previous NAFLD studies in swine allow ad libitum access to diets.
Furthermore, many of these studies also relied on the reduction of choline (Lee et al.,
2009; Liang et al., 2015; Raubenheimer et al., 2006; Rinella et al., 2008), as well as the
addition of colic acid (Yamada et al., 2017) in order to achieve the development of
NAFLD.
Similar to pediatric models, models dedicated to the pathogenesis of NAFLD in
non-obese patients pediatric lean NAFLD are lacking. While obesity is undoubtably a
major risk factor for the development of NAFLD, there exists a subpopulation of patients
that develop NAFLD without the typical risk factors, such as obesity or metabolic
syndrome. Lean NAFLD manifests in the liver similarly non-lean NAFLD, except it
develops in patients with body mass indexes lower than 25 kg/m2 (Wattacheril and
Sanyal, 2016). It is estimated that prevalence of NAFLD occurring in lean subjects is
approximately 7-9% (Kumar and Mohan, 2017). In addition, it has been shown that the
occurrence of lean NAFLD is associated with younger age (Kumar and Mohan, 2017;
Wang et al., 2017). Lean NAFLD may even present a more dangerous form of NAFLD,
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as the lack of adequate adipose tissue available to accept fatty acids causes the
redistribution of fat to muscle and liver (Wattacheril & Sanyal, 2016). While models of
NAFLD in swine typically develop obesity, there have been studies in mice that were
able to develop the histological features of NAFLD without significantly increasing the
body weight of adults (Matsuzawa et al. 2007; Tu et al. 2017).

5

Table 1.1: Summary of recent swine models of non-alcoholic fatty liver disease (NAFLD).
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1.4 Histological characteristics and serum markers of pediatric NAFLD
In children and adults, liver biopsy and histological analysis are the most accurate
method of diagnosing NAFLD. While the characteristic histological features of
NAFLD/NASH, including steatosis, inflammation, ballooning and fibrosis, are the same
between adults and children, the manifestation of these features may differ. In both
populations, steatosis can be defined as the presence of intracytoplasmic fat, in the form
of triacylglycerides, in >5% of hepatocytes (Tiniakos et al., 2010). One of the first
distinctions between adults and children in the progression of NAFLD is the distribution
of steatosis. In clinical reviews, researchers have found that steatosis in pediatric
populations typically begins in periportal zones or has azonal distribution, whereas adults
began in perivenular zones (Giorgio et al., 2013; Nobili et al., 2006; Schwimmer et al.,
2005;). Additionally, steatosis is primarily macrovacuolar (Berardis and Sokal, 2014).
Conversely, NASH is defined by the presence of >5% macrovesicular steatosis,
inflammation and hepatic ballooning of any degree (Tiniakos et al., 2010).
Often times indirect measures of NAFLD, such as blood parameters, are used to
diagnose NAFLD as an alternative to liver biopsy. Hepatic enzymes alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) are the most common
serum markers of liver injury, and are typically elevated in adults (Neuschwander‐Tetri
and Caldwell, 2003; Tiniakos et al., 2010). While serum levels of these aminotransferases
may be moderately elevated in children, the often fluctuate, and can even appear to be in
normal range in children with NAFLD (Berardis and Sokal, 2014; Giorgio et al., 2013).
In pediatric populations, other biochemical abnormalities such as increased levels of
gamma-glutamyl transferase (GGT), bilirubin, and albumin have been seen; however,
7

they typically remain within normal ranges unless the patient is developing more sever
forms of NASH or cirrhosis (Giorgio et al., 2013; Roberts, 2007). Pediatric patients with
NASH often have an increase in blood levels of pro-inflammatory cytokines such as
TNF-α and IL-6, which is thought to be a result of expansion of adipose tissue (Berardis
and Sokal, 2014). It is seldom that other blood parameters appear out of range for
children, but in adults and models of NAFLD, lactate dehydrogenase (LDH) and blood
urea nitrogen (BUN) levels are typically elevated in those with NAFLD (Dhibi et al.,
2011; Hashemi Kani et al., 2013).
1.5 Role of inflammatory cytokines and transcription factors in NAFLD
Pro-inflammatory cytokines are known to play a critical role in the pathogenesis
of NAFLD and the progression to NASH. In turn, patients who are diagnosed with
NAFLD typically have increased levels of cytokines in the blood and liver (Berardis and
Sokal, 2014). The result of the increased production of these cytokines is not only to
increase local inflammation, but also to promote additional hepatocyte cell injury, leading
to the release of damage associated molecular patterns (DAMPs) (Arrese et al., 2016).
DAMPs are intracellular molecules that are released or secreted during cellular injury or
death, such as high-mobility group box 1, nuclear and mitochondrial DNA, and purine
nucleotides (Arrese et al., 2016). For example, tumor necrosis factor alpha (TNFα) not
only induces neutrophil infiltration, but also stimulates mitochondrial oxidant production,
increasing their sensitivity to undergo apoptosis, and ultimately producing DAMPs.
(Braunersreuther et al., 2012; Lee and Friedman, 2011). Additionally, interleukin 1 alpha
(IL-1α) has been shown to increase the expression of inflammatory and fibrosis related
genes, as well as the expression of adhesion molecules and chemotactic factors, which
8

promote the progression to NASH (Kamari et al., 2011). By increasing cellular damage
and the production of DAMPs, these cytokines further increase hepatocellular injury by
activating Kupffer cells via toll-like receptor 4 (TLR4). Upon the ligand binding of
DAMPs to TLR4, an intracellular pro-inflammatory signaling cascade is stimulated, and
ultimately can lead to the production of more pro-inflammatory cytokines, and the
activation of hepatic stellate cells (Kesar and Odin, 2014). In this way, these proinflammatory cytokines create a positive feedback loop to perpetuate the occurrence of
inflammation and liver injury. Models of NAFLD in juvenile Ossabaw swine had
analogous results in liver gene expression, where pigs fed a Western diet also had
increased levels of cytokines, as well as TLR4 and ACTA2 (Panasevich et al., 2018).
Fat metabolism is regulated by transcription factors in the liver, such as
carbohydrate-response element-binding protein (ChREBP), Sterol regulatory elementbinding transcription factor 1 (SREBP1c) and peroxisome proliferator-activated receptor
gamma (PPARγ). Typical expression of PPARγ is low in the liver; however, in animal
models of fatty liver disease expression of PPARγ is significantly increased
(Malaguarnera et al., 2008). This is consistent with other studies that found that increased
PPARγ expression was correlated with lipid accumulation in the liver and upregulation of
its target gene, CD36 (Inoue et al., 2005). One of the roles of CD36 is to facilitate the
transport of long-chain fatty acids into the cell, so it is plausible that the increase in
PPARγ expression ultimately leads to increased importation of fatty acids from the HFF
diet into hepatocytes, to ultimately be used for TAG synthesis (Rivera et al., 2007). In
addition to the diet, many studies examine the role of DNL and its contribution to the
development of NAFLD. Previous studies have found that as much as 26% of liver TAG
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content was derived from DNL in patients with NAFLD (Tamura and Shimomura, 2005).
In mice models, the increase in the rate of DNL can be determined by an increase in
regulatory transcription factors such as liver X receptor alpha (LXRα), SREBP-1c, and
ChREBP (Cha and Repa, 2006; Tamura and Shimomura, 2005). Interestingly, a study
conducted in human NAFLD patients also found that those with NAFLD had decreased
ChREBP levels compared to control patients, suggesting that SREBP-1c, not ChREBP, is
the transcriptional factor responsible for the transcription of DNL enzymes acetyl-CoA
carboxylase alpha (ACACA) and fatty acid synthase (FASN), and that LXRα may not
control for the transcription of ChREBP (Higuchi et al., 2008). Because ChREBP is
regulated by glucose, it is possible that when insulin resistance occurs in the hepatocytes,
it also dysregulates the induction of ChREBP (Cohen et al., 2011; Higuchi et al., 2008).
1.6 Role of one-carbon metabolism and TCA cycle in NAFLD
For detailed information of dysregulation of these pathways in NAFLD, see Fig. 2.5 and
Fig. 2.6.
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2. A DIET-INDUCED PEDIATRIC MODEL OF NON-ALCOHOLIC FATTY
LIVER DISEASE USING NEONATAL IBERIAN PIGS
2.1 Introduction
Non-alcoholic fatty liver disease (NAFLD) represents the emerging cause of
pediatric liver disease, affecting approximately 10% of children worldwide (Clemente et
al., 2016). In the United States, the prevalence of pediatric NAFLD is estimated to be
0.7% in 2-4 years old infants to 17.3% in adolescents (Schwimmer et al., 2006). The
disease is characterized by intrahepatic lipid accumulation without the excessive
consumption of alcohol, progressing from the simple steatosis, to nonalcoholic
steatohepatitis (NASH), characterized by inflammation and hepatocellular injury, and in
advanced cases, cirrhosis and liver failure (Younossi et al., 2016). The increasing
presence of pediatric NAFLD and its potential severity in children creates a critical need
to further investigate and understand the pathogenesis of NAFLD in pediatric
populations. Unfortunately, a translational model does not exist to date that fully
recapitulates the characteristics of pediatric liver disease.
Previous studies have identified an association between high-carbohydrate, highfat diets (Western diet) and the prevalence of pediatric NAFLD, suggesting an important
role of fat and sugar intake in the pathogenesis of the disease (Solga et al., 2004). More
specifically, consumption of a Western diet is thought to contribute to the pathogenesis of
NAFLD by dysregulating the insulin signaling pathway, elevating the rate of de novo
lipogenesis and increasing the formation of triacylglycerides (TAG) derived from dietary
free fatty acids (Cohen et al., 2011; Lim et al., 2010). Indeed, metabolic syndrome, which
is characterized by obesity, diabetes, hyperdyslipemia, and insulin resistance, have been
linked to pediatric NAFLD (Marchesini et al., 2003). However, it remains unclear if
11

metabolic syndrome is necessary for the development of NAFLD, or simply a related
consequence of a Western diet. The molecular mechanisms involved in the pathogenesis
of NAFLD are still not fully understood. In an attempt to provide insight on the etiology
of NAFLD, studies have begun to investigate the metabolomic profile of the liver and
blood in cases of NAFLD in order to elucidate metabolic pathways affected by the
disease. Of particular interest, one-carbon metabolism has been identified as a key
metabolic pathway involved in the pathogenesis of NAFLD. One‐carbon metabolism is
required for the synthesis of formylated methionyl‐tRNA, the catabolism of choline,
purines, and histidine, and the interconversion of serine and glycine (Fox and Stover,
2008). In particular, choline metabolism is a key mediator of the progression of NAFLD,
due to its involvement in lipid metabolism, methylation-dependent biosynthesis of
molecules, and mitochondrial bioenergetics (Corbin and Zeisel, 2012). In addition to onecarbon metabolism, lipidomics and aminomics have revealed key insights into the
pathogenesis of NAFLD. Despite these revelations, no pediatric model of NAFLD to date
has examined the combination of these metabolic pathways and their interactions with
each other in the pathogenesis of the disease.
As the prevalence of NAFLD increases, studies have focused on discovering
therapeutic treatments to ameliorate disease progression and potentially reverse the
effects of a Western diet. The role of the gut microbiome has become a critical question
in the progression of NAFLD, as the liver and gastrointestinal tract are intrinsically
linked via portal circulation, and the gut microbiome has been shown to play a role in
related factors such as body weight, insulin sensitivity, and glucose metabolism (Brun et
al., 2007; Cani and Delzenne, 2007). Subsequently, probiotics have arisen as a potential

12

therapeutic strategy to manage NAFLD by improving the intestinal barrier, which may
inhibit toxins such as lipopolysaccharides (LPS) from entering portal circulation and
reaching the liver (Abenavoli et al., 2013). While recent studies have shown that
probiotic administration in both pediatric and adult populations can improve the clinical
symptoms of NAFLD, conflicting results have also been reported where probiotics were
unable to prevent liver steatosis or inflammation in mice with diet-induced NASH
(Famouri et al., 2017; Loguercio et al., 2005; Velayudham et al., 2009). It is therefore
unclear whether probiotic supplementation presents a successful therapeutic strategy to
attenuate the progression of NAFLD. Furthermore, there has been little to no research
focused on the use of probiotics to prevent the onset of NAFLD in children.
Finally, most clinical models of NAFLD to date have relied on rodent models,
despite differences between rodents and humans in terms of pathogenesis and progression
of NAFLD (Larter and Yeh 2008). Pigs represent a more accurate translational model of
liver disease, and more specifically, the Iberian pig has recently emerged as a potential
research model of NAFLD because of their elevated voluntary feed intake and extreme
lipogenic potential (Spurlock and Gabler, 2008; Torres-Rovira et al., 2012). However, a
translational model of pediatric liver disease has not been developed to date, as previous
NAFLD models used either adults subjects or involved lengthy feeding protocols that
extended beyond the infant stage and often provide unrestricted diets (Table 1.1).
Taken together, the objective of this study was to develop a diet-induced,
pediatric model of NAFLD in neonatal Iberian pigs by controlled administration of a
Western diet, and to investigate molecular mechanisms underlying the pathogenesis of
the disease, as well as their interactions. We hypothesized that 13-d old Iberian pigs fed a
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high-fat high-fructose (HFF) diet during 10 consecutive weeks would develop a pattern
of liver injury resembling pediatric NAFLD. In addition, we sought to determine if
supplementation of a commercial probiotic mixture of Lactobacillus plantarum,
Pediococcus acidilactici, Pediococcus pentosaceus, and Bacillus amyloliquefaciens in a
HFF diet will prevent the development of NAFLD.
2.2 Material and methods
2.2.1 Animal and experimental design
Experiments were carried out in accordance with the Institutional Animal Care
and Use Committee (IACUC #1611) of California State University and conducted in
accordance with the National Research Council (NRC) Guide for the Care and Use of
Laboratory Animals (NRC, 2011).
The following experimental design pertains to Experiment 1. Nine Iberian pigs
from the Iberian Pig Research Colony at California Polytechnic State University were
weaned at 10 d old and moved into a temperature-controlled room (28ºC) with a 12‐h/12‐
h light‐dark cycle. Pigs were housed in pairs in 1.524 × 1.524 m pens balanced for sex
and weight, and bowl-fed ad libitum a commercial milk replacement diet (Soweena® Dry
Fat 7-60TM; Merrick Animal Nutrition, Middleton, WI, USA) for 3 d. On d 13, pens
were randomly assigned to receive 1 of 2 liquid diets (g · kg body weight (BW)-1 ∙ d-1;
Table 2.1): 1) control (CON-N; n = 4): 0 g fructose, 11.2 g fat and 199.3 kcal
metabolizable energy (ME), and 2) high-fructose high-fat 1 (HFF1-N; n = 5): 10.1 g
fructose, 20.6 g fat and 314.8 kcal ME. The CON-N diet was formulated to meet the
nutrient requirements of 5-6 kg pigs according to the NRC (2012), whereas HFF1-N diet
was formulated to exceed by 60% the ME but to meet the animal protein requirements
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(Tables 2.1 and 2.2). The desire ME in HFF1-N was achieved by increasing both the corn
oil (Healthy Brand Oil Corporation, NY, USA) and the animal fat blend (Fat-Pak 80;
MilkSpecialities Global, Eden Prairie, MN, USA) content in the CON-N diet, and adding
hydrogenated lard (Armour, TX, USA) and fructose (Tate&Lyle, IL, USA), with 25%,
55% and 19% of ME in HFF1-N provided by carbohydrates, fat and protein sources,
respectively. The liquid diets were mixed every 3 d using a 24 L food blender (LAR25LMB; Skyfood, Miami, FL, USA) and tap water, and stored at 4ºC in a commercial
refrigerator. Animals were fed 45 mL · kg BW-1 at 6-h intervals 4 times per d starting at
0700, with the liquid diets poured into 2 bowls per pen to decrease competition between
the animals. To prevent diarrhea in the piglets, HFF1-N was gradually increased until
week 5 of the study by diluting it with CON-N. The first day the experimental diets were
fed was considered as d 0 of the study. Body weights were recorded every 3 d, and
average daily gain (ADG) was calculated for the 70 d period. Animals were euthanized
on d 70 of the study (83 d of age) at 8-h post feeding using an intramuscular injection (4
mg ∙ kg BW-1) of tiletamine and zolazepam (Telazol®; Zoetis, Parsippany, NJ, USA),
followed by an intracardiac injection of pentobarbital sodium (0.4 mL · kg BW-1;
Schering-Plough, Union, NJ, USA). Tissue samples from liver and skeletal muscle (i.e.
longissimus dorsi; LD) were weighed, frozen immediately in liquid nitrogen and stored at
-80ºC, or fixed in 10% neutral buffered formalin until further analysis. Liver, heart and
kidneys were removed and weighed (Fig. 2.1D). Quantitative assessment of lean mass
was calculated using the hot carcass weight (lb), loin eye area at the 10th rib (square
inch) and fat depth over the loin eye (inch), according to the formula 100 × [8.588 +
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(0.465 × hot carcass weight) - (21.896 × 10th rib fat depth) + (3.005 × 10th rib loin
muscle area)]/hot carcass weight, as previously described (Burson, 2010).
The following experimental design pertains to Experiment 2. Twenty four 10-d
old Iberian pigs were housed in the same facility and handled as described previously. On
d 13, all pig were randomly distributed to receive 1 of the 4 liquid diets (Table 2.2): 1)
CON-N (n = 4): 0 g fructose, 11.2 g fat and 199.3 kcal ME (kg BW-1 ∙ d-1), 2) CON-P (n
= 8): CON + 6.2 × 104 cfu ∙ mL-1 (0.2 g ∙ L-1) probiotics, 3) HFF2-N (n = 6): 21.6 g
fructose, 16.2 g fat and 301.0 kcal ME, and 4) HFF2-P (n = 6): HFF2 + 6.2 × 104 cfu ∙
mL-1 probiotics. The feeding protocol was as described in Exp. 1, with the HFF2-N and
HFF2-P gradually increased until week 5 by diluting diets with CON-N and CON-P,
respectively. The CON-N and HFF2-N diets were prepared every 3 d as described in Exp.
1. To prevent bacteria overgrowth, CON-P and HFF2-P diets were mixed daily by adding
a commercial mixture of Pediococcus acidilactici, Pediococcus pentosaceus,
Lactobacillus plantarum and Bacillus amyloliquefaciens (BiOWiSH® MultiBio 3PS;
BiOWiSH Technologies, Cincinnati, OH, USA) to CON-N and HFF2-N using a
commercial agitator (Grovhac Inc, Brookfield, WI, USA) at 300 rpm for 2 min. Both
CON-N and CON-P diets had the same ingredient composition as described for CON-N
in Exp.1, whereas HFF2-N and HFF2-P diets were formulated to exceed by 50% the ME
but to meet the pig protein requirements (Tables 2.1 and 2.2). The increase in ME in
HFF2-N and HFF2-P diets was achieved by removing the corn oil from the diet,
decreasing the animal fat blend and dextrose (Tate & Lyle) content, and adding
hydrogenated coconut oil (Tate & Lyle), hydrogenated lard and fructose to the CON-N
diet, with 35%, 44% and 19% of ME provided by carbohydrates, fat and protein sources,
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respectively. Animal BW, ADG, organ weights and tissue samples were collected as
described in Exp. 1.
2.2.2 Probiotic detection and viability
To detect probiotic DNA in the diets, samples randomly collected during the
study were diluted at 1:8 ratio in lysogeny broth (LB; Fisher Scientific, Fair Lawn, NJ,
USA) and incubated at 37˚C for 48 h in an Innova 42 incubator shaker (New Brunswick,
Hauppauge, NY, USA). Detection of probiotic DNA was carried out by PCR using
bacteria-specific primers for each bacteria (Table A.3) using Taq 2X Master Mix (New
England BioLabs Inc, Ipswich, MA, USA) on a T100 thermocycler (Bio-Rad, Hercules,
California, USA). Bacterial genomic DNA and nuclease-free water were used as positive
and negative controls, respectively. All PCR reactions were performed with the following
thermal cycling conditions: 5 min at 95°C, followed by 40 cycles of 95°C for 30 s, 55°C
for 30 s, 68°C for 30 s, and a final extension step at 68°C for 7 min. Product length and
yield was analyzed by electrophoresis in 2.5% agarose gels with 1.0 μg/ml of ethidium
bromide (Sigma-Aldrich, St. Louis, MO, USA). Gels were analyzed using a Gel Doc
XR+ system and Image Lab 5.0 software (Bio-Rad). The PCR products were purified
from the agarose gel using a NucleoSpin® Extract II kit (Clontech Laboratories,
Mountain View, CA, USA) and sequence verified at UC Davis DNA Sequencing Facility
(Davis, CA, USA).
To detect probiotic DNA across the gastrointestinal tract, luminal content from
proximal jejunum (PJ), distal ileum (DI), colon, cecum, and rectum was flushed with icecold 0.9% sterile saline solution into 50 mL sterile tubes (VWR® High-Performance
Centrifuge Tubes, VWR, Visalia, CA, USA), flash frozen in liquid N, and stored at -
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80˚C. Bacterial DNA was isolated in duplicates using a DNeasy PowerLyzer PowerSoil
Kit (QIAGEN, Germantown, MD, USA) according to manufacturer’s instructions, and
both DNA yield and purity assessed using a NanoDrop 1000 (ThermoFisher Scientific,
Waltham, MA, USA). To minimize the risk of contamination, samples from each section
and diet were processed on different days. All PCR reactions, and visualization,
purification and sequencing of PCR products were carried out as described above. To
evaluate probiotic viability in HFF-P and CON-P diets, samples from each diet were
collected at 24 h after mixing, aliquoted in triplicates, diluted at 1:100 in 0.1% sterile
peptone (Fisher Science, Fair Lawn, NJ, USA) and spread plated with solid glass beads
(Fisher Scientific) on Tryptic Soy agar (TSA; BD Difco™, Tryptic Soy Agar, Fisher
Scientific) and De Man, Rogosa and Sharpe (MRS) agar (GranuCultTM MRS agar,
Millipore Sigma, Burlington, Massachusetts, CA, USA). Plates were incubated at 37˚C in
aerobic conditions and colonies were counted at 24, 48 and 72 h.
2.2.3 Serum biochemistry
Blood was sampled from the jugular vein at 2 h post-feeding on d 40 and 65.
Samples were centrifuged at 2,100 rpm for 15 min at 4˚C, and both plasma and serum
stored in 1.5 mL tubes at -80˚C. Serum lipid and liver biochemistries were analyzed by
the Comparative Pathology Laboratory (CPL) at University of California, Davis (Davis,
CA, USA) using a Roche Integra 400 Plus (Roche Diagnostics, Pleasanton, CA, USA).
2.2.4 Serum insulin, glucose, leptin, and cytokines
To assess fasting levels of insulin, glucose, and leptin, blood samples were
collected at 8 h post-feeding on d 70. Blood was taken from the left ventricle immediately
before euthanasia by using a 2-inch 14 G needle, and serum and plasma samples

18

processed as described above. Insulin, leptin and glucose levels were analyzed by the
Animal Health Diagnostic Center (AHDC) at Cornell University (Ithaca, NY, USA)
using a human insulin radioimmunoassay (RIA) kit (Millipore Sigma, Burlington, MA,
USA), a multi-specie leptin RIA kit (Millipore) and a Cobas c501 (Roche Diagnostics),
respectively. Insulin resistance was estimated from fasting glucose and insulin
concentrations using the homeostatic model assessment (HOMA), according to the
formula: [fasting insulin (µU ∙ mL-1) × fasting glucose (mg ∙ dL-1)]/405. Serum levels of
tumor necrosis factor alpha (TNFα), interleukin 1 alpha (IL-1α) and transforming growth
factor beta (TGFβ) were analyzed by the Cytokine Core Laboratory (CCL) at University
of Maryland (Baltimore, MD, USA) using a pig-specific enzyme-linked immunosorbent
assay (ELISA).
2.2.5 Triacylglyceride content and histological and proliferative analysis
Total triacylglyceride (TAG) content in liver and LD tissue was determined using
the InfinityTM Triglyceride Reagent (ThermoFisher Scientific, Waltham, MA, USA)
according to previously described methods (Jouihan 2012). Liver tissue from the left
medial lobe was fixed in 10% neutral buffered formalin at room temperature, then
transferred to 70% ethanol and submitted to the Comparative Pathology Laboratory
(CPL) at the University of California, Davis (Davis, CA, USA). Tissues were embedded
into standard paraffin blocks, and 5-µm-thick sections were stained with hematoxylin and
eosin (H&E) for histological analysis. Fresh liver and LD samples were also embedded in
optimum cutting temperature compound 4583 (Sakura Finetek USA Inc., Torrance, CA,
USA), gradually frozen in 2-methylbutane (Sigma-Aldrich) cooled with liquid nitrogen
and stored at -80ºC. Frozen blocks were cut with a thickness of 5 µm at the Histology
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Core at Baylor College of Medicine (BCM; Houston, TX, USA) and stained with Oil Red
O. The liver stains were examined by an experienced pathologist (D.I.; CPL) blinded to
the treatment groups. Steatosis, ballooning degeneration, Mallory-denk bodies, lobular
inflammation, fibrosis and necrosis were semi-quantitatively evaluated for each pig, and
a composite lesion score (CLS) was calculated. Zonal distribution of each of these
variables was also systematically annotated. Steatohepatitis (NASH) was defined by the
presence of macrovesicular steatosis ≥ 1, hepatocellular ballooning ≥ 1, and lobular
inflammatory infiltrates ≥ 1, as previously recommended (Wattacheril & Sanyal., 2016).
To determine the number of proliferative cells in pig liver tissue, Ki67
immunostaining was performed on formalin-fixed and paraffin-embedded tissue by the
Histology Core at BCM. Sections were pretreated using heat-mediated antigen retrieval
with citrate buffer for 20 min, followed by incubation with an anti-Ki67 antibody at
1:1000 for 15 min (Abcam, Cambridge, MA, USA). The Ki67 antibody was detected
using the BondTM Polymer Refine Detection Kit (Leica Biosystems, Buffalo Grove, IL,
USA) on a Leica Bond-III automated system (Leica Biosystems). Slides were dehydrated
through a series of alcohols and xylene, and a coverslip was applied using a permanent
mounting media (ThermoFisher Scientific). The immunostained slides were examined
under bright field microscopy using an Olympus BX53 microscope fitted with an
Olympus DP73 digital camera and cellSens software (Olympus; Center Valley, PA,
USA). Each transverse section was divided into 5 quadrants, and 2 fields of view per
quadrant were captured with a final magnification of 200 X. The number of Ki67-positive
hepatocytes was determined by manual counting in 5 random visual fields (1 field per
quadrant) using the multi-point tool in ImageJ software (National Institutes of Health,
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Bethesda, MA, USA). Counts were averaged, and the ratio between the labeled Ki67+
(brown-stained) and total hepatocyte count was expressed as percentage for each sample.
2.2.6 Gene expression analysis
Total RNA was extracted from 100 to 150 mg of frozen liver using guanidinium
thiocyanate-phenol-chloroform method with TRIzol reagent (ThermoFisher Scientific),
and subsequently purified using RNeasy Mini Kit (QIAGEN, Hilden, Germany). Purity
and yield of RNA was assessed with a NanoDrop 1000 (ThermoFisher Scientific),
whereas integrity was analyzed by electrophoresis in a 1.2% RNA agarose gel with 1.0
μg∙ml-1 of ethidium bromide (Sigma-Aldrich). The QuantiTect Reverse Transcription Kit
(QIAGEN) was used to reverse transcribed 200 ng of RNA per sample, and resulting
cDNA was diluted 1:6 with free RNAse water (Sigma-Aldrich). Quantitative PCR
(qPCR) was performed on an ABI Prism 7500 (Applied Biosystems, Foster City, CA,
USA) using Power SYBR Green PCR Master Mix (Applied Biosystems). All qPCR
reactions were performed with the following thermal cycling conditions: 2 min at 50°C,
10 min at 95° C, followed by 40 cycles of 95° C for 15 sec and 60°C for 60 sec, and a
final dissociation curve (95° C for 15 sec, 60° C for 60 sec, and 95° C for 15 sec). A
relative standard curve was used as the qPCR method to measure relative mRNA
abundance of candidate and reference genes (Larionov et al., 2005). Duplicate relative
amounts from the standard curve for each sample were -log2-transformed and averaged to
improve the normality of the residuals and homogeneity of the variance (Steibel et al.,
2009; Manjarin et al., 2011). Normalization of target genes (i.e. ΔCts) was made by
dividing the relative quantities of each target gene by the geometric mean of relative
quantities of 3 reference genes selected with geNorm software, as previously described
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(Vandesompele et al., 2002). Gene expression results are presented as inverted ΔCts,
whereby ΔCts are subtracted from the same positive entire number (i.e. 5 - ΔCt), so
higher values correspond to higher relative mRNA abundance (Manjarin et al., 2011).
The constant was selected to be an entire number greater than any ΔCt in the data set, so
all values presented in the figures are positive.
Primer sequences for reference and target genes are presented as Supplementary
Material (Table A.2). Primers were designed to span exon-exon junctions using the
PrimerQuest Tool software (Integrated DNA Technologies, Coralville, IA, USA) based
on publicly available swine reference sequences deposited in the National Center for
Biotechnology Information (NCBI). Primer pairs were tested by PCR using GoTaq Green
Master Mix (Promega, Madison, WI, USA) on a T100 thermocycler (Bio-Rad) with the
following thermal cycling conditions: 2 min at 95°C, followed by 40 cycles of 95°C for
30 sec, 60°C for 30 sec, 72°C for 30 sec, and a final extension step at 72°C for 5 min.
Visualization, purification and sequence-verification of the PCR products was performed
as described for probiotic primers. Efficiency of the qPCR reaction for each primer pair
was calculated from a 2-fold 5-point standard curve according to the formula (2-1/slope -1)
× 100.
2.2.7 Western Blot analysis
Approximately 100 mg of liver and muscle tissues were separately homogenized
and sonicated in a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, and 0.5% of
20% (w/v) sodium dodecyl sulfate (SDS) solution) with a mixture of protease inhibitors
(500 mM B-glycerophosphate, 10 mM EDTA, 10 mM NaF, 1 mM sodium
orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 1 ug leupeptin/mL, and a
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protease inhibitor cocktail (P8340-5ML; Sigma Aldrich, St. Louis, MO). Samples were
incubated with agitation for 2 h, centrifuged, and supernatant protein contentcentration
was measured using a BCA assay (Pierce™ BCA Protein Assay Kit, #23225, Thermo
Scientific). Thirty five μg of protein extractions from liver and muscle were
electrophoretically separated on 7-12% SDS polyacrylamide gels (PAGE; C.B.S
Scientific, Del Mar, CA, USA) and transferred to PVDF transfer membranes (Thermo
Scientific, Rockford, IL, USA). After blocking with 5% BSA, the membranes were
incubated overnight with primary antibodies, followed by 1 h incubation with secondary
antibody. Blots were developed using an enhanced chemiluminescence kit (ECL Select
Western Blotting Detection Readgent; GE Health Sciences, Buckinghamshire, UK),
visualized, and analyzed using a ChemiDoc-It Imaging System® (BIO-RAD, Hercules,
CA, USA). For normalization, immunoblots performed with anti-phosphospecific
antibodies were exposed to stripping buffer (Pierce Biotechnology, Rockford, IL, USA)
and reprobed with non-phosphospecific antibodies against total protein (Cell Signaling
Technology, Danvers, MA, USA). Primary antibodies used were against protein kinase B
(PKB Ser473 and total; Cell Signaling Technology), microtubule-associated protein
1A/1B light chain 3A (LC3 I/II; Cell Signaling Technology), ubiquitin-binding protein
p62 (Cell Signaling Technology), extracellular signal-regulated kinase (ERK Thr
202/204; Cell Signaling Technology), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; Cell Signaling Technology).
2.2.8 Metabolomics
Targeted metabolomic assays for primary metabolomics, aminomics, and
lipidomics were performed on plasma and liver samples using protein precipitation
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extraction with ultra-performance liquid chromatography tandem quadrupole mass
spectrometry (UPLC-MS) using modified previously published methods (Townsend et al.
2013). Briefly, 25 µL of plasma or 40-60 mg liver samples were added to 1.5 mL tubes
before being spiked with 20 µL isotopically-labeled surrogates, followed by 750 µL
chilled methanol. Samples were then vortexed 1 min prior to being centrifuged at 2,000 X
g for 10 min. The supernatant was transferred to 1.5 mL high performance liquid
chromatography (HPLC) amber glass vials, dried by centrifugal vacuum evaporation, and
reconstituted in 3:1 methanol:acetonitrile containing 100 nM of 1 cyclohexyl ureido, 3
dodecanoic acid (Sigma-Aldrich, St. Louis, MO, USA). The reconstituted solution was
vortexed 1 min and filtered at 0.1 µm by centrifugation at 2,000 g for 10 min through
PVDF Durapore membranes (Millipore, Billerica, MA, USA). All UPLC-MS analyses,
including primary metabolomics, aminomics, and lipidomics, were conducted on a
Waters Acquity I-Class UPLC (Waters, Milford, MA, USA) coupled with an API 4000
QTrap (Sciex, Framingham, MA) using multiple reaction monitoring quantified with AB
Sciex MultiQuant version 3.0. For the primary metabolomics assay, metabolites were
separated using a 150 X 2.0mm Luna NH2 column (Phenomenex, Torrance, CA) and
detected by negative ion mode electrospray ionization (Townsend et al. 2013; Bajad et al.
2006). For the aminomics assay, metabolites were separated using a 150 × 2.1 mm
Atlantis HILIC column (Waters, Milford, MA, USA) and detected by positive ion mode
electrospray ionization (Townsend et al., 2013; Wang et al., 2011). For the lipidomics
assay, metabolites were separated using a 150 × 3.0 mm Prosphere HP C4 column
(Grace, Columbia, MD, USA) and detected by positive ion mode electrospray ionization
(Townsend et al. 2013; Rhee et al. 2011).
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2.2.9 Statistical analysis
Categorical variables were analyzed by ANOVA using a mixed model in SAS 9.2
(PROC MIXED; SAS Institute Inc., Cary, NC, USA) that included diet, probiotic and
their interactions as fixed effects, and pen nested in treatment as random effect. A
repeated measurement statement was included to analyze the BW of the animals, with the
structure of the covariance selected based on smallest Akaike information criterion.
Normality of the residuals and presence of outliers were assessed with PROC
UNIVARIATE (SAS). Non-normally distributed parameters were power transformed by
a parameter φ whose optimal value was estimated using the maximum likelihood (ML)
method (Piepho 2009). Multiple comparisons were accounted for with Tukey test. Data is
presented as least square means ± SE. Significant effects were considered at P ≤ 0.05.
Differences in hepatic histological features between groups were analyzed by KruskalWallis with Bonferroni multiple comparisons test for non-parametric data in SAS (PROC
NPAR1WAY and PROC RANK).
Metabolomics data was imported into the Primer-E software (v.6; Primer-E Ltd.,
Plymouth, United Kingdom), log transformed into a normal distribution approximation
and analyzed with a Euclidean distance matrix. A non-parametric multivariate analysis of
variance (PERMANOVA; Primer-E Ltd) was used for testing the null hypothesis of no
difference between groups, based on the parameters’ permutation of residuals under a
reduced model, 9999 permutations and a type III sum of squares. Further multivariate
modeling was conducted using partial least squares-discriminant analysis (PLS-DA) with
MetaboAnalyst 4.0 (Xia Lab, McGill University, Montreal, Quebec, Canada; Chong et al.
2018; Xia and Wishart 2016), to visualize any clustering effects related to the diet and
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probiotics. Data were Pareto scaled and cross validated using leave-one-out-validation
(LOOV) to assess model performance using Q2 and R2 metrics. Identification of
metabolites differentially expressed between groups was performed by a 2-way ANOVA
with the same random and fixed effects described above. The Benjamini-Hochberg
procedure (Benjamini and Hochberg 1995) with a cutoff of 5% was used to adjust the
reported P-values to control for the rate of false discoveries.
2.3 Results
The effect of CON-N diet on BW, ADG, organ weight, serum parameters,
histology, and gene expression was not significantly different between pigs on Exp.1 (n =
4) and Exp. 2 (n = 4), so data for these animals was combined for statistical analysis
(CON-N; n = 8).
2.3.1 Experiment 1
Results for Exp. 1 are presented as Supplementary Material and in Table A.1.
There were no differences between groups in initial age, BW on d 0 and 65, ADG and
fasting leptin levels on d 70. Insulin and glucose were not measured in HFF1-N animals.
Compared to CON, HFF1-N increased relative liver weight on d 70 (P ≤ 0.01; Table
A.1), serum levels of alanine aminotransferase (ALT) and total protein on d 40 (P ≤ 0.01
and P ≤ 0.05, respectively), and non-esterified fatty acids (NEFA) on d 65 (P ≤ 0.05). In
addition, HFF1-N decreased total cholesterol (P ≤ 0.01) and low-density lipoproteins
(LDL; P ≤ 0.01) on d 65, and blood urea nitrogen (BUN) on both d 40 and 65 (P ≤ 0.01).
The grade of steatosis was higher in HFF1-N compared to CON-N (P ≤ 0.01), with all
HFF1-N livers showing macrovesicular steatosis with centrilobular distribution.
Ballooning degeneration, Mallory-Denk bodies, inflammation, necrosis, and fibrosis were
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not observed in CON-N and HFF1-N, whereas CLS was higher in HFF-N than in CON-N
(P ≤ 0.05). None of the CON-N and HFF1-N animals was classified as NASH. Compared
to CON, HFF1-N increased gene expression of toll-like receptor 4 (TLR4; P ≤ 0.05),
whereas transforming growth factor beta (TGFβ), tumor necrosis factor alpha (TNFα),
interleukin 1α (IL1α), interleukin 1β (IL1β) and smooth muscle alpha (α)-2 actin
(ACTA2) did not differ between diets (Fig. A.1).
2.3.2 Probiotic detection and viability
The remainder of the results will pertain to Experiment 2. To facilitate readership
through the manuscript, when diet × probiotic interaction (i.e. CON-N, CON-P, HFF2-N
and HFF2-P) is not significant only the main effect of diet (i.e. CON vs HFF2) and
probiotics (i.e. N vs P) will be reported and discussed. Figure 2.3A presents colony
counts for diets at 24, 48 and 72 h after plating in TSA and MRS agar plates. Tryptic soy
agar is a general-purpose media, while MRS is selective for Lactobacillus. Initial
inoculate count was 6.2 × 102 cfu ∙ mL-1 for CON-P and HFF2-P in both agar plates.
Compared to CON-P, HFF2-P increased colony counts at 72 h in TSA (P ≤ 0.05; 15.7 ±
2.4 cfu ∙ mL-1 vs 10.0 ± 2.4 cfu ∙ mL-1) but not in MRS (6.0 ± 0.9 cfu ∙ mL-1 vs 5.3 ± 0.9
cfu ∙ mL-1). A small number of background colonies of different size and color than those
formed by probiotics were detected in all agar plates due to the preparation of the diets
with tap water and in non-sterile conditions. The PCR amplification of DNA isolated
from the 4 diets with strain-specific primers for Pediococcus acidilactici, Pediococcus
pentosaceus, Lactobacillus plantarum and Bacillus amyloliquefaciens yielded products
of the expected size and sequence in both HFF2-P and CON-P, whereas CON-N and
HFF2-N were negative (Fig. 2.3A). Similarly, PCR products corresponding to Bacillus
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amyloliquefaciens were detected at 8-h post-feeding in contents from PJ, DI, cecum,
colon and feces in CON-P and HFF2-P but not in HFF2-N or CON-N diets (Fig. 2.3B).
Amplification of PCR products for both Pediococcus strains were detected in PJ, DI,
cecum, colon and feces in all diets but CON-N, whereas Lactobacillus plantarum was not
detected in the small and large intestine contents of any of the pigs (Fig. 2.3B).
2.3.3 Body weight, body composition, average daily gain, and tissue weights
Age, initial BW, and average daily gain (ADG) between d 0 and 70 did not differ
among the 4 diet groups. Pig BW was higher in CON-P compared to HFF2-N and HFF2P between d 55 and d 70 (P ≤ 0.05), and on d 55, 58 and 67 compared to CON-N (P ≤
0.05; Fig. 2.1C). Loin muscle area on d 70 was higher in CON compared to HFF2 (P ≤
0.05), whereas percentage of lean mass, hot carcass weight and dorsal fat remained
constant across treatments (Fig. 2.1E). Relative liver weight (g liver ∙ kg BW-1) was
higher in HFF2-N compared to CON-N and CON-P (P ≤ 0.001), and increased further in
HFF2-P (P ≤ 0.05), while relative kidney weight was higher (P ≤ 0.01) in HFF2
compared to CON (Fig. 2.1D). Relative heart weight did not differ between diets.
2.3.4 Hormones, glucose and pro-inflammatory cytokines
Probiotic (P) increased fasting insulin levels and HOMA values (P ≤ 0.05), and
tended to increase glucose levels (P ≤ 0.1) compared to non-probiotic (NP) animals,
whereas leptin was higher (P ≤ 0.05) in HFF2 compared to CON (Fig. 2.3C). Serum
levels of TGF-β, IL1α and TNFα remained unchanged between groups (Fig. 2.3C).
2.3.5 Serum biochemistry
Serum biochemistry is presented in Figure 2.1.F, Figure 2.6.B, and Figure 2.7.B.
Compared to CON, HFF2 increased on d 40 and 65 the serum levels of alanine
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aminotransferase (ALT; P ≤ 0.001), aspartate aminotransferase (AST; P ≤ 0.01 and P ≤
0.001), alkaline phosphatase (ALP; P ≤ 0.001), gamma glutamyl transferase (GGT; P ≤
0.05 and P ≤ 0.01), lactate dehydrogenase (LDH; P ≤ 0.01 and P ≤ 0.001), whereas total
bilirubin increased (P ≤ 0.01) only on d 65. Likewise, TAG levels increased (P ≤ 0.05) on
d 40 in HFF2 compared to CON. Blood urea nitrogen was also higher (BUN; P ≤ 0.001)
on d 40, and total protein (P ≤ 0.01 and P ≤ 0.001) and albumin (P ≤ 0.001) on d 40 and
65 in HFF2 compared to CON. Conversely, on d 40 and 65 of the study HFF2 decreased
total cholesterol (P ≤ 0.001 and P ≤ 0.01, respectively), and high (HDL; P ≤ 0.05 and P ≤
0.001) and low-density lipoproteins (LDL; P ≤ 0.001 and P ≤ 0.05) compared to CON,
whereas LDL/HDL ratio was lower only on d 40 (P ≤ 0.05). Serum levels of nonesterified fatty acids (NEFAs) remained constant across groups.
2.3.6 Triacylglyceride content and histological analysis
Compared to CON, HFF2 diet increased TAG content in both liver (P ≤ 0.001;
Fig. 2.2D) and LD (P ≤ 0.001). Steatosis was classified as macrovesicular with
centrilobular distribution in CON animals, and macro and microvesicular with periportal
or diffuse distribution in the HFF2 group (Table 2.3), and was increased in HFF2
compared to CON (P ≤ 0.01; Fig. 2.2A and F). Ballooning grade was significantly higher
in HFF2-N than in CON-N and CON-P (P ≤ 0.01), and increased further in HFF2-P
compared to HFF2-N (P ≤ 0.05), whereas the score of Mallory-Denk bodies was higher
only in HFF2-P compared to CON-N and CON-P (P ≤ 0.05; Fig. 2.2A and Table 2.3).
Inflammation and necrosis were increased in HFF2 compared to CON (P ≤ 0.001; Fig.
2.2A and Table 2.3). Composite lesion scores (CLS) were also higher in HFF2 than in
CON diets (P ≤ 0.05; Fig. 2.2C and Table 2.3) but fibrosis was not observed in any of the
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liver samples (Fig. 2.2F and Table 2.3). Four pigs (66.6%) in HFF2-N and 6 (100%) in
HFF2-P developed NASH, whereas none of CON-N and CON-P was classified as NASH
due to the absence of hepatocellular ballooning (P ≤ 0.01; Fig. 2.2B). Finally, Ki67
immunostaining showed an increase in Ki67 proliferative cell index in HFF2 compared to
CON pigs (P ≤ 0.001; Fig. 2.2E and F).
2.3.7 Gene expression and protein analysis
Cyclin-G-associated kinase (GAK), vacuolar protein sorting-associated protein
4A (VPS4A) and porphobilinogen deaminase (HMBS) were selected as reference genes
in geNorm. Inclusion of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was not
necessary as the pairwise variation parameter (V) was already below the suggested cutoff
value of 0.15 (Fig 2.4A-B). Gene expression data is presented in Fig. 2.4C-E. Compared
to CON, HFF2 increased gene expression of TNFα (P ≤ 0.05), TGFβ (P ≤ 0.01), IL1α (P
≤ 0.05), TLR4 (P ≤ 0.05) and peroxisome proliferator-activated receptor gamma (PPARγ;
P ≤ 0.01), and decreased carbohydrate-responsive element-binding protein (ChREBP; P
≤ 0.001). Expression of IL1β, ACTA2, sterol regulatory element-binding protein 1
(SREBP-1c), liver X receptor alpha (LXR-α), fatty acid synthase (FASN), acyl-CoA
synthetase long-chain 1 (ACSL-1), and fatty-acid-binding protein (FABP) did not change
between groups.
Protein expression levels are represented in Fig. 2.3D. In the liver, probiotic (P)
increased protein levels of p62 (P = 0.002), LC3I/II (P ≤ 0.001) and ERK (P ≤ 0.001),
and tended to increase PKB (P = 0.052) compared to non-probiotic (NP) animals.
Compared to CON, HFF2 had increased protein levels of LC3I/II (P ≤ 0.001) in muscle.
There was no difference in protein levels of PKB or p62 in the muscle.
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2.3.8 Metabolomics
Metabolomic data is represented in Fig. 2.5, 2.6 and 2.7. A total of 224 and 218
metabolites were detected in plasma and liver, respectively. The multivariate analysis
showed that there was no probiotic effect, therefore, only the main effect of diet (i.e.
CON vs HFF2) will be reported and discussed. We subsequently identified 105 and 64
metabolites in liver and plasma, respectively, with significant changes between CON and
HFF2 pigs using a false discovery rate (FDR) of P ≤ 0.05 in a two-way ANOVA.
Compared to CON, pigs fed HFF2 diet showed an increase in cholesterol esters (CE) in
the liver, while there was a significant decrease in cholesterol in the plasma. However,
the major bile salts glycocholate and taurocholate, were significantly increased in both
the liver and the plasma. Levels of diacylglycerols (DAG), specifically C36:1 and C36:2,
were increased in the HFF2 livers compared to CON, but showed no change in the
plasma. In the HFF2 liver, triacylglycerols (TAG) with carbon chain lengths of 52 to 58
were decreased compared to CON, whereas carbon chain lengths of 44 to 50 were
increased compared to control, suggesting a preference towards shorter chain TAG. In the
plasma, pigs fed HFF2 diets had significantly decreased levels of TAG compared to
CON, with an exception of C50:0, C50:1, and C50:2.
Upon examining phospholipids, there was an inconsistent change in levels of
sphingomyelin (SM). In the liver, pigs fed HFF2 diets had increased SM with carbon
chain lengths of 16 to 18 and 24, and decreased SM with carbon chain lengths of 20 to
23, when compared to CON. Similarly in the plasma, SM with chain lengths of 24 were
increased in HFF2 compared to CON, and chain lengths of 15, 20 and 21 were decreased.
When looking at glycerophospholipids, we found that levels of phosphatidylcholines
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(PC) were decreased in HFF2 livers compared to CON, with an exception of C32:0,
C32:1, C38:2, and C38:3. Only phosphatidylethanolamine (PE) C36:0 was significantly
different in the liver, where pigs fed HFF2 diets had significantly increased levels
compared to CON. In the plasma, there was far fewer significantly changed
glycerophospholipids. Compared to CON, pigs fed HFF2 diets had significantly
decreased levels of PC 34:2, PC 38:5, and PE 36:1, and significantly increased levels of
PC

38:2.

In

the

liver,

the

levels

of

glycerophospholipid

metabolites,

lysophosphotidylcholines (LPC) and lysophosphoethanolamines (LPE), were both
significantly elevates in pigs fed HHF2 diets compared to CON. Contrarily, in the plasma
pigs fed HFF2 had decreased levels of LPC and no change in LPE compared to control.
Metabolites connected to β-oxidation, such as carnitine and oleyl carnitine, were
significantly increased in HFF2 livers compared to CON. Similarly, plasma levels of
carnitine and acetyl carnitine were significantly increased in pigs fed HFF2 compared to
CON. In the HFF2 liver, certain metabolites pertaining to one carbon metabolism were
decreased, such as acetylcholine, 4-pyridoxate, betaine, glycine and choline; whereas
others, such as serine, methionine, and homocysteine, were increased compared to CON.
Plasma levels of pigs fed HFF2 showed parallel results with significant decreases in 4pyridoxate, betaine, glycine and choline, and an increase in homocysteine. In HFF2 livers
there was a marked decrease in nucleic acids guanine, uridine, xanthine, adenosine,
cytosine, xanthosine, and guanosine compared to CON. In the plasma, a decrease in the
nucleic acid component deoxycytidine was seen in pigs fed HFF2 compared to CON.
Metabolites involved in the urea cycle and the tricarboxylic acid (TCA) cycle,
such as arginine, ornithine, fumarate and malate, were significantly increased in HFF2
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livers compared to control. While these metabolites did not show significant changes in
the plasma, HFF2 pig had a significant decrease in citrulline and an increase in succinate,
both utilized in the urea cycle and the TCA cycle, respectively. Metabolomics showed a
significant decrease in creatinine, a biproduct of the urea cycle, and a significant increase
in lactate, the alternative route for pyruvate, in the livers of pigs fed HFF2 diets. The
decrease in creatinine was also seen in the plasma. Amino acids and there derivatives
were significantly altered in pigs fed HFF2 diets, where there was an increase in
isoleucine, kynurenic acid, kynurenine, leucine, phenylalanine, phosphotyrosine, and
tyrosine, and a decrease in anthranilic acid, glutamine, histamine, and lysine. Similar
results were found in the plasma, where pigs fed HFF2 diets had increased levels of
kynurenine, phenylalanine, and tryptophan, and decreased levels of glutamine and lysine.
Several metabolites unrelated to the previously mentioned pathways were altered in the
livers of pigs fed HFF2 diets compared to CON, including a decrease in hippurate and an
increase in oxalate and sorbitol. Contrarily, the plasma of HFF2 fed pigs showed a
decrease in oxalate, as well as a decrease in serotonin when compared to CON.
2.4 Discussion
2.4.1 Feeding a high-fructose high-fat diet for 10 weeks induced NASH
Non-alcoholic fatty liver disease represents an emerging chronic liver disease in
pediatric populations, increasing the risk of liver transplant in infants, as well as the
development of long-term complications such as cardiovascular disease, type 2 diabetes
and liver-related death at adult age (Berardis and Sokal, 2014). Despite the high
prevalence and severe complications, the etiology and pathophysiology of pediatric
NAFLD is not fully understood, in part due to the lack of animal models dedicated to the
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liver disease in children. Pigs represent an excellent translational model for liver research,
due to the similarities between pigs and humans in liver size and structure,
gastrointestinal physiology and lipoprotein profiles (Chapman and Goldstein, 1976;
Douglas, 1972; Spurlock and Gabler, 2008; Swindle et al., 2012). Particularly, the Iberian
and the Ossabaw pig, which is a direct descendant from the Iberian breed, have recently
emerged as excellent research models of metabolic syndrome and NAFLD, because of
their elevated voluntary feed intake and extreme lipogenic potential (Mayer and Brisbin
1991; Torres-Rovira et al. 2012; Gonzáles-Bulnes et al. 2014; Fernández-Fígares et al.
2007). However, most diet-induced models of NAFLD in Iberian and Ossabaw pigs, as
well as in other breeds such as Göttingen, Bama and Yucatan minipigs, have been
recreated only in adult animals, in which feeding starts around 6 months of age (Table
1.1). Further, causative mechanisms such as ad libitum feeding, choline/methionine
deficient diets or inclusion of sodium cholate were needed to induce NAFLD, decreasing
the significance of the translational models to investigate the consequences and molecular
mechanisms elicited by specific components in the diet.
Given the data previously reported in pig models and their limitations, the aim of
the present study was to develop and characterize the first pig model of pediatric NAFLD
in which animals were fed controlled amounts of a “Western diet” that met the essential
nutrient requirements while providing a 50% excess in daily recommended caloric intake
(National Research Council, 1998). Notably, 100% of the pigs fed the HFF2 diet
presented steatosis and increased levels of hepatic enzymes in blood after 5 weeks, and
83% were classified as NASH at 83 d of age. With Iberian pigs reaching maturity at 160180 d, 11-week-old animals correspond approximately to 8 or 9-year-old children, which
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to our knowledge represents the youngest translational age in a diet-induced pig model of
pediatric NAFLD (Table 1.1). The fast time course of the disease is likely related to the
fixed leptin receptor (LEPR) mutation in the Iberian breed, which similarly to the Zucker
fatty rat (Phillips et al., 1996), is associated with a leptin resistance phenotype
characterized by hyperphagia, obesity, and elevated levels of circulating leptin in
comparison to other porcine breeds (Fernández-Fígares et al., 2007; Munoz et al., 2009).
In addition, feeding diets in liquid form instead of regular chow may have enhanced liver
injury by shifting the microbiome (Mastrocola et al., 2018), decreasing the satiety signals
(Pan et al., 2011) and/or increasing BW (DiMeglio and Mattes, 2000). Interestingly,
HFF1 and HFF2 diets provided the same caloric intake, but only HFF2-fed animals
developed histopathological lesions observed in pediatric NASH, including macro and
microvesicular

steatosis,

hepatocellular

ballooning,

Mallory

hyaline,

lobular

inflammation and necrosis (Schwimmer et al., 2005). While is not possible to identify the
dietary components responsible for the differences in liver damage between diets, the
critical role in the progression to NASH of ingredients in HFF2 such as cholesterol and
saturated fats has been documented before (Tu et al., 2017; Wang et al., 2017). The effect
of HFF2 fat components in promoting hepatic TAG accumulation is further outlined by
the observed increase in lipids with shorter carbon chain and lower number of double
bonds in the liver of HFF2 pigs, likely attributable to the elevated content in saturated
medium-chain fatty acids in the coconut oil.
Although a pattern of hepatic lesions without fibrosis has been observed in up to
30% of children diagnosed with type 1 NASH (Carter-Kent et al., 2009), the lack of
perisinusoidal or portal fibrosis in the HFF2 group was unintended and represents a
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limitation in our pediatric model, likely due to the short duration of the study. Neonate
Iberian pigs were fed for only 10 weeks, whereas fibrotic lesions were first observed at
16 and 32 weeks in previous diet-induced pig models of NASH (Gutiérrez-Vidal et al.,
2018; Lee et al., 2009; Li et al., 2016; Liang et al., 2015; Panasevich et al., 2018;
Schumacher-Petersen et al., 2019; Yang et al., 2015). Elevated levels of cell proliferation
in the liver of HFF2 pigs, as demonstrated by Ki67 staining (Fig. 2.2), may indicate
initial progression towards a neoplastic condition associated with NASH. Cirrhotic
NASH is known to progress to hepatocellular carcinoma (HCC); HCC incidence with
cirrhotic NASH ranges between 2.4-12.8% (Perumpail et al., 2015). Furthermore, there is
a growing body of literature demonstrating HCC incidence in non-cirrhotic NASH
(Perumpail et al., 2015). The pathogenesis of NASH-HCC is incompletely understood
and multifaceted; proposed mechanisms include genetic or epigenetic modifications and
alterations in metabolic, immunologic, and endocrine pathways (Kutlu et al., 2018).
Many studies demonstrate the role of bile acids (BAs) in hepatocarcinogenesis (Kim et
al., 2007; Xie et al., 2016; Yamada et al. 2018; Yoshimoto et al., 2013). Mice lacking
expression of farnesoid X receptor (FXR), a BA-activated nuclear receptor that serves as
the master regulator of BA homeostasis, spontaneously developed HCC (Kim et al.
2007). Secondary BAs, which are BAs that have been modified by bacterial enzymes in
the intestinal lumen, promote proliferation of hepatocytes through multiple mechanisms,
including promotion of the mTOR pathway (Yamada et al., 2018) and induction of a
HCC-related cellular phenotype (Yoshimoto et al., 2013). Strikingly, HFF2 pigs were
demonstrated to have elevated concentrations of primary BAs taurocholate and
glycocholate in their livers, elevated total plasma BAs, elevated relative abundance of
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taurodeoxycholic acid (TDCA) in the colon, and increased BA synthesis (Smith et al.,
under review). Deoxycholic acid (DCA), a secondary BA, is able to permeate cell
membranes. Thus, it is reasonable to speculate that elevated levels of TCDA in the colon
would translate to elevated hepatic exposure to TDCA, due to its ability to pass from the
colon into enterohepatic circulation and permeate hepatocellular cell membranes. Taken
together, increased exposure to genotoxic BAs may represent one mechanism by which
hepatocellular proliferation was promoted in HFF2 pigs.
2.4.2 Hepatic dysregulation of one-carbon metabolism in pediatric NAFLD
While pediatric NAFLD has been associated to obesity, insulin resistance (IR)
and type-2 diabetes in children, the primary metabolic dysregulations leading to TAG
accumulation in the liver are not well understood, as patients are diagnosed after
developing the disease. The prevailing two-hit model of NASH implies IR to promote the
initial steatosis, followed by inflammation and fibrosis in response to multiple factors
including oxidative stress and mitochondrial dysfunction (Biczo et al., 2018). This study
reports for first time in a large animal model of pediatric NASH the development of
significant hepatomegaly and over 10-fold increase in hepatic TAG accumulation without
changes in BW, IR and systemic inflammation, suggesting a diet-induced metabolic
abnormality in the liver at the center of the pediatric disease. To identify potential
mechanisms accounting for the HFF2-induced hepatic steatosis, we quantified the
expression of different genes involved in fatty acid and cholesterol metabolism in the
liver. Consistent with the lack of obesity and IR, expression of enzymes and transcription
factors involved in de novo lipogenesis and fatty acid trafficking in the hepatocyte
remained unaltered or decreased in response to the HFF2 diet, and only PPARγ, which
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has been previously associated with regulation of hepatic fatty acid uptake (Yu et al.,
2003), increased in response to the HFF2 diet.
A key finding in our model was the markedly decrease in choline availability in
liver and plasma, which in rodent models on non-obese NAFLD has been shown to
reduce the substrate for hepatic synthesis of PCs, impairing the assembly of VLDLs and
the subsequent fat export from the liver (Itagaki et al., 2013; Rinella et al., 2008). Further
supporting the prediction of a blockage in hepatic TAG outflow is the decrease in
circulating levels of cholesterol, LDLs and HDLs in HFF2 compared to control pigs,
despite the significantly higher fat content in the HFF2 diet. A link between dysfunctional
VLDL metabolism and the progression to NASH has also been described in clinical
studies in adults (Fujita et al., 2009), and a growing body of literature suggests the
development

of

NAFLD

in

non-obese

patients

with

lower

prevalence

of

hypertriglyceridemia and IR but increased hepatic inflammation (Dela Cruz et al. 2014;
Margariti et al., 2013). Although the current study does not address the origin of choline
decline, our diets were formulated to meet the choline requirements in growing pigs
(National Research Council, 1998), suggestive of a metabolic rather than a dietaryinduced choline deficiency in the NAFLD animals. Within hepatocytes, choline may
enter the CDP-choline pathway for PC synthesis or serve as source of methyl groups via
oxidation to betaine, which is then used for remethylation of homocysteine to methionine
to further generate SAM, the main methyl donor in the liver (Corbin et al., 2012; Obeid,
2013). Consequently, the observed decrease in choline and betaine levels along with
higher levels of methionine in HFF2 animals suggest that an excess of methylation
activity may have reduced the choline and betaine pool in the liver. Evidence of
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decreased choline and betaine availability in the context of hepatic steatosis has been
shown in adults with NASH (Sokooian et al., 2017) and patients receiving parenteral
nutrition, in which choline replacement led to a reversal of hepatic fat infiltration
(Buchman et al., 2001). Similarly, supplementation of choline in a mixture with vitamin
E and docosahexaenoic acid improved steatosis in pediatric NASH (Zöhrer at al., 2017).
Albeit increased levels of homocysteine are commonly found in adults with
NAFLD (de Carvalho et al., 2013; Dai et al., 2016; Hu et al., 2016 ), and correlated with
the severity of liver damage in children (Pastore et al., 2014), the mechanisms leading to
hyperhomocysteinemia are poorly understood. Besides remethylation into methionine,
homocysteine is also converted into cysteine via transsulfuration by the enzyme
cystathionine β-synthase, which requires both serine and vitamin B6 (Ubbink et al.,
1996). The decrease in vitamin B6 catabolic product 4-pirodoxate in liver and plasma of
HFF2 pigs, along with the accumulation of serine in liver, is supportive of the idea that
impaired catabolism of homocysteine via the transsulfuration pathway may have
contributed to the increase in homocysteine and methionine in our animals.
Concomitantly, a deficiency in the vitamin B6, which is also crucial coenzyme of serine
hydroxymethyltransferase for the synthesis of 5,10-methylenetetrahydrofolate in the
folate cycle (Ubbink et al., 1996), may explain the decrease in purines and pyrimidines
observed in the HFF2 group. While increased levels of homocysteine are well described
in NAFLD patients, conflicting results exist in the literature regarding changes in
methionine metabolism in diet-induced NAFLD. Given that an impairment in the
methionine adenosyltransferase (MAT) would be expected to increase homocysteine but
also to reduce SAM availability in the liver, this pathway is unlikely to have contributed
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to methionine elevation in HFF2 pigs. Previous studies in mouse NAFLD models suggest
hepatic methionine levels to be both time and disease-dependent, with increased levels
associated to early changes in hepatic transsulfuration reactions (Kwon et al., 2009), and
a depletion in longer feeding trials in parallel to the progression to NASH (Pacana et al.,
2015). Accordingly, the increase of hepatic methionine stores in our study may be a
temporary event, caused by either a methionine overload in response to higher
homocysteine levels, or a compensatory mechanism to maintain SAM availability under
NAFLD conditions.
2.4.3 Nitrogen metabolism is dysregulated in pediatric NAFLD
In addition to the dysregulation of carbon one metabolism, NAFLD is associated
to the dysregulation of mitochondrial function (Wei et al., 2008). Specifically, NAFLD
has been shown to be linked to the disruption of the urea cycle and the TCA cycle (De
Chiara et al. 2018; Wei et al. 2008). In the present study, pigs fed an HFF2 diet
significantly altered levels of amino acids and metabolites associated with the urea cycle
and the TCA cycle (Figure 2.6). Of particular interest was the decrease in blood levels of
BUN and the increase in lactate found in the liver of pigs fed HFF2 diets. Urea is the
main biproduct of the urea cycle, and is excreted from the liver through the blood as
BUN. Therefore, the decrease in BUN levels is indicative of a urea cycle disorder
(Steiner and Cederbaum, 2001). Although ammonia levels were not measured, we can
assume that a decrease in the urea cycle would cause an accumulation of ammonia, which
have been shown to lead to the progression of NAFLD (De Chiara et al. 2018).
Furthermore, the increase in lactate levels suggests a loss of mitochondrial function and
ultimately an increased reliance on ‘anaerobic’ metabolism, and has also been associated
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with hepatic disorders (Ghosh and Callier, 2012; Nolan et al., 2008). The dysregulation
of the TCA cycle and the urea cycle can causes an increase in energy substrates available,
which can then be shunted towards the production of TAGs, and ultimately increase
steatosis (Kowalski et al., 2016). Overall, pigs fed a HFF2 diet showed an increase in
amino acids catabolized through the TCA cycle, which could be due to a build-up if these
cycles were deregulated. Additionally, pigs fed HFF2 diets showed decreased loin eye
area, as well as decreased activity levels (shown in unpublished data), suggesting an
increase in the catabolism of proteins and ultimately the increase in the amino acid pool.
2.4.4 Probiotic supplementation did not ameliorate HFF-induced NAFLD
Recently, studies have shown that probiotic administration in both pediatric and
adult populations can improve the clinical symptoms of NAFLD (Famouri et al. 2017,
Loguercio et al. 2005). In the present study, a probiotic cocktail of Lactobacillus
plantarum, Bacillus amyloliquefaciens, Pediococcus pentocaceus, and Pediococcus
acidilactici was administered to the pigs at 6.2 × 104 cfu/mL. The colony counts of our
probiotic cocktail on MRS and TSA plates demonstrated that probiotics were viable in
the milk, and thus had the potential to survive in the digestive tract of the pig. Although
there were colony counts in milk samples that were not supplemented with probiotics,
due to differences in colony morphology, it was concluded that bacteria came from tap
water as opposed to cross contamination. Furthermore, a PCR analysis using probiotic
specific primers for all bacteria in the milk validated the primers and supported that no
cross contamination had occurred. Finally, PCR analysis of the gut contents suggested
that bacterial DNA from B. amyloliquefaciens, P. pentocaceus, and P. acidilactici could
be found in all portions of the gut, with an exception of the PJ. Although bands could be
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seen in the contents of pigs that were not supplemented with probiotics, the PCR analysis
of the milks leads us to believe that this is likely due to endogenous bacteria in the gut.
In rodent models of NAFLD, each of these probiotic species have been shown to
have therapeutic effects against NAFLD, including protection against obesity, decreasing
steatosis, decreasing liver cytokine levels, and downregulating genes associates with lipid
uptake and de novo lipogenesis (Kim et al., 2018; Li et al., 2014; Moon et al., 2014; Shi
et al., 2017; Zhao et al., 2012). It is known that lipopolysaccharides (LPS) derived from
Gram-negative bacteria in the gut can bind with TLR4 in the liver, which plays a role in
liver injury and inflammatory signaling. Probiotics are thought to attenuate NAFLD by
improving the intestinal barrier, which may inhibit LPS from entering portal circulation
and reaching the liver (Xue et al., 2017). Contrary to these findings, pigs fed HHF2-P did
not have a reduction in the clinical symptoms of NAFLD. In fact, pigs fed HFF2-P diet
had increased presence of steatosis, Mallory-Denk bodies, and hepatic ballooning.
Additionally, probiotic supplementation did not alter the intestinal barrier, as there was
no changes in villi length, crypt depth, or gene expression of occludin (Smith et al., under
review). Though probiotic supplementation is generally regarded as a successful
therapeutic strategy, studies have shown did not prevent liver steatosis or inflammation in
mice with diet-induced NASH (Velayudham et al., 2009). While probiotics did not
demonstrate therapeutic effects in the clinical symptoms of NAFLD, pigs fed CON-P
diets resulted in increased body weight towards to end of the study, when compared with
all other treatments. Although this effect is not seen in humans, studies have shown that
probiotic supplementation on early weaned pigs can improve piglet growth performance
in an industry setting (Dong et al., 2013, Veizaj-Delia et al., 2010). It is important to note
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that all of these probiotic findings can only be attributed to this specific probiotic mixture
fed in a liquid diet form.
Similar to obesity, insulin resistance is highly correlated to the occurrence of
NAFLD. While insulin resistance occurs in the majority of all children diagnosed with
NAFLD, there is significantly lower prevalence of insulin resistance in patients with lean
NAFLD, as well as models of non-obese NAFLD (Matsuzawa et al. 2007; Roberts, 2007;
Schwimmer et al., 2003; Tu et al. 2017; Younossi et al., 2012; Zhang et al., 2016). In the
present study resulting in non-obese pigs, consumption of a HFF diet and the
development of NASH did not result in insulin resistance based on fasting insulin levels,
fasting glucose levels, HOMA values, and protein levels of PKB in the liver and muscle.
Surprisingly, fasting insulin levels, HOMA values, and PKB in the liver were all
increased in pigs supplemented with probiotics, regardless of diet. Although insulin
levels and HOMA values were higher, true insulin resistance was not achieved as PKB
would be decreased in the instance of hepatic insulin resistance (Samuel and Shulman,
2016). We speculate that the increased insulin levels may be related to an impairment of
insulin clearance pathways. A majority of insulin is cleared in the liver, where it is
degraded via autophagy (Yamamoto et al., 2018). Interestingly, we found a probiotic
affect in autophagy as LC3 I/II levels were increased in pigs supplemented with
probiotics. LC3 I is converted to LC3 II upon the formation of a mature autophagosome,
and serves as a recognition site for p62, which delivers its cargo to autophagosomes to be
destroyed (Gonzales-Rodriguez et al., 2014). In normal conditions, an activation of the
autophagic flux would cause a decrease in the amount of p62, as p62 is destroyed with its
cargo upon delivery to the lysosome (Gonzales-Rodriguez et al., 2014). However, if p62
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is also increased, this suggests an impairment of the autophagic flux as opposed to an
increase in the rate of autophagy, as autophagosomes are not being destroyed. In the
present study, there was an increase in p62 in pigs fed CON-P and HFF2-P diets,
suggesting an impairment of autophagy due to probiotic supplementation. Additionally,
there was an increase in the phosphorylation of ERK in pigs fed CON-P and HFF2-P.
Although the results pertaining to autophagy were unexpected, probiotics, including L.
plantarum, have been shown to activate ERK pathway in previous studies (Dai et al.,
2012). Although ERK is involved in numerous cell processes, increased activation of the
ERK pathway has been shown to disrupt autophagy at the maturation phase, resulting in
the buildup of defective autophagosomes, as demonstrated in the present study (Corcelle
et al., 2006). However, further investigation is necessary to determine the mechanism
behind the dysregulation of autophagy as a result of probiotic supplementation.
Contrarily, no probiotic effect was seen in the muscle, rather a diet effect where pigs fed
HFF diets had higher abundance of LC3 I/II and p62. Impaired autophagy has been seen
in both mice and minipig models of diet induced NAFLD, and is thought to further the
progression of NAFLD by promoting endoplasmic reticulum stress and the accumulation
of lipid droplets in hepatocytes (Gonzales-Rodriguez et al., 2014, Li et al., 2016).
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Table 2.1: Daily nutrient (g ∙ kg BW-1 · d-1) and metabolizable energy (ME; kcal · kg
BW-1 · d-1) of control (CON-N; CON-P), high-fructose high-fat 1 (HFF1-N) and highfructose high-fat 2 (HFF2-N; HFF2-P) diets fed to 10-d old pigs during 10 consecutive
weeks. Values expressed as fed.
Feed amount (L∙kg BW-1∙d-1)
DM (g∙kg BW-1∙d-1)
CP (g∙kg BW-1∙d-1)
ME (kcal∙kg BW-1∙d-1)
CHO (g∙kg BW-1∙d-1)
EE (g∙kg BW-1∙d-1)
Amino Acids (SID, g∙kg BW-1∙d-1)
Arg
His
Ileu
Leu
Lys
Met
Cys
Phe
Tyr
Thr
Trp
Val
Fatty Acids (SID, g∙kg BW-1∙d-1)
Caprylic
Capric
Lauric
Myristic
Palmitic
Stearic
Arachidic/eicosanoic
Behenic
Palmitoleic
Oleic
Gadoleic
Linoleic
Linolenic
Arachidonic
Cholesterol (g∙kg BW-1∙d-1)
Ca (g∙kg BW-1∙d-1)
P (g∙kg BW-1∙d-1)
Fructose (g∙kg BW-1∙d-1)
Dextrose (g∙kg BW-1∙d-1)

CON-N, CON-P
0.18
40.78
13.19
199.26
12.82
11.17

HFF1-N
0.18
60.99
13.25
314.75
23.01
20.56

HFF2-N, HFF2-P
0.18
63.92
13.09
300.97
30.05
16.24

0.30
0.27
0.78
1.44
1.11
0.26
0.32
0.41
0.32
0.76
0.20
0.70

0.31
0.27
0.78
1.45
1.11
0.26
0.32
0.41
0.32
0.76
0.20
0.70

0.30
0.26
0.77
1.43
1.10
0.26
0.32
0.40
0.32
0.75
0.20
0.69

0.00
0.00
0.00
0.07
1.78
0.67
0.01
0.00
0.14
3.48
0.06
3.86
0.04
0.02
0.03
0.62
0.43
0.00
10.80

0.00
0.01
0.02
0.19
3.99
1.83
0.07
0.00
0.39
7.41
0.15
5.25
0.11
0.04
0.04
0.62
0.43
10.08
10.79

0.48
1.07
3.39
1.38
2.58
1.28
0.06
0.00
0.23
3.88
0.08
0.96
0.06
0.02
1.30
0.62
0.43
21.60
6.30

BW: body weight; DM: dry matter; CP: crude protein; ME: metabolizable energy; CHO:
carbohydrates; EE: ether extract; SID: standard ileal digestibility; Ca: calcium; P:
phosphorus
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Table 2.2: Ingredient composition of control (CON-N; CON-P), high-fructose high-fat 1
(HFF1-N) and high-fructose high-fat 2 (HFF2-N; HFF2-P) diets fed to 10-d old pigs
during 10 consecutive weeks.
CON-N, CON-P
HFF1-N
Whey protein concentrate
8.50
8.5
Fructose2
0.00
5.60
Dextrose2
6.00
5.99
Fat Pak 803
3.20
5.27
4
Hydrogenated lard
0.00
3.20
Hydrogenated coconut oil2
0.00
0.00
Corn oil5
3.20
3.68
6
Xanthan gum
0.40
0.40
Vitamin premix7,8
0.32
0.32
7,8
Mineral premix
1.20
1.20
Cholesterol7
0.00
0.00
Water
77.2
65.8
1
80% Whey Protein Concentrate; BFD Nutrition, AZ, USA
1

HFF2-N, HFF2-P
9.00
12.0
3.50
1.75
3.10
4.20
0.00
0.40
0.32
1.20
0.70
63.8

2

Tate & Lyle, IL, USA

3

Advanced Fat-Pak 80; Milk Specialties Global Animal Nutrition, MN, USA

4

Armour, TX, USA

5

Healthy Brand Oil Corporation, NY, USA

6

NutraBlend, MO, USA

7

Dyets Inc., Bethlehem, PA, USA.

8

Provided per kg vitamin premix: vitamin A, 4,409,171 IU; vitamin D 3, 661,376 IU;

vitamin E, 17,637 IU; vitamin B 12, 15.4 mg; menadione, 1764 mg, riboflavin, 3307 mg;
D-pantothenic acid, 11,023 mg; niacin, 19,841 mg; phytase, 200,000 FTU. Provided per
kg mineral premix: Fe, 110,000 mg; Zn, 110,000 mg; Mn, 26,400 mg; Cu, 11,000 mg; I,
200 mg; Se, 200 mg
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Table 2.3: Histologic features of liver samples in pigs fed Control (CON-N), Control +
probiotics (CON-P; 6.2 × 104 cfu/mL), high-fructose high-fat 1 (HFF1-N), high-fructose
high-fat 2 (HFF2-N), or high-fructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104 cfu/mL)
during 10 consecutive weeks. Liver tissue was collected on d 70 at 8 h post-feeding.
Item
Steatosis
Grade

Type
Zonal distribution

Ballooning degeneration
Grade

Mallory-Denk bodies
Grade

Inflamation
Grade

Fibrosis
Grade

Necrosis
Grade

Zonal distribution

Composite lesion scores

Score/code

CON-N

CON-P

HFF1-N

0 (absent)
1 (< 10%)
2 (10 - 25%)
3 (26 - 50%)
4 (> 50%)
macrovesicular
microvesicular
random
centrilobular
midzonal
periportal
submassive (2 of above)
diffuse (all zones)

6 (8)
2 (8)

3 (8)
5 (8)

0 (absent)
1 (minimal)
2 (mild)
3 (moderate)
4 (severe)

8 (8)

0 (absent)
1 (minimal)
2 (mild)
3 (moderate)
4 (severe)

8 (8)

8 (8)

5 (5)

0 (absent)
1 (minimal)
2 (mild)
3 (moderate)
4 (severe)

1 (8)
7 (8)

8 (8)

5 (5)

0 (absent)
1 (minimal)
2 (mild)
3 (moderate)
4 (severe)

8 (8)

8 (8)

5 (5)

0 (absent)
1 (minimal)
2 (mild)
3 (moderate)
4 (severe)
random
centrilobular
midzonal
periportal
submassive (2 of above)
diffuse (all zones )
0-11

8 (8)

8 (8)

5 (5)

1 (5)
4 (5)

2 (8)

5 (8)

5 (5)

2 (8)

5 (8)

5 (5)

8 (8)

5 (5)

HFF2-N

HFF2-P

2 (6)
4 (6)
6 (6)
2 (6)

1 (6)
4 (6)
1 (6)
6 (6)
1 (6)

1 (6)

1 (6)

5 (6)

5 (6)

2 (6)
4 (6)

4 (6)
2 (6)

5 (6)
1 (6)

2 (6)
4 (6)

6 (6)

1 (6)
5 (6)

8 (8)

8 (8)

6 (6)

5 (6)

1 (6)
n/a

n/a

n/a
6 (6)

5 (6)

1 (6)
1.12

47

1.8

2.8

6.5

8.3
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Fig. 2.1 Physical and serum results pertaining to NASH. Experimental timeline for
animal weighing, diet mixing, probiotic addition, blood sampling, euthanasia and tissue
collection for experiment 1 and experiment 2 (A). Representative images of pigs fed
CON and HFF2 diets on d 70 (B). Body weight between d 0 and 70 (C), representative
liver images taken immediately after removal and relative organ weight of liver, heart,
and kidney (D), average lean mass composition (%) (E), and average serum levels of
alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl
transferase (GGT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) on d
40 and d 65 at 2-h post feeding (F) from pigs fed control (CON-N), control + probiotics
(CON-P; 6.2 × 104 cfu/mL), high-fructose high-fat 2 (HFF2-N), and high-fructose highfat 2 + probiotics (HFF2-P; 6.2 × 104 cfu/mL) diets during 10 weeks. . Values are least
square means ± SE. *P ≤ 0.05.
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Fig. 2.2 Histological results of the liver. Average histological scores of steatosis,
hepatic ballooning, Mallory-Denk bodies, inflammation, and necrosis (A), occurrence of
steatosis with and without NASH (B), averagebox and whisker plots of composite liver
score calculated by the addition of all histological scores (C), triacylglycerol (TAG)
concentration (D), % Ki-67+ cells/field (E), and representative microphotographs of
hematoxylin-eosin (H&E), trichrome, oil red O, and Ki-67 stains (F) in liver tissue from
pigs fed control (CON-N), control + probiotics (CON-P; 6.2 × 104 cfu/mL), high-fructose
high-fat 2 (HFF2-N), and high-fructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104
cfu/mL) diets during 10 weeks. Values are least square means ± SE. a,b,cP ≤ 0.05, d,e,fP ≤
0.01, g,h,iP ≤ 0.001.
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Fig. 2.3 Probiotic detection and effects. In vitro colony count in control (CON-N),
control + probiotics (CON-P; 6.2 × 104 cfu/mL), high-fructose high-fat 2 (HFF2-N), and
high-fructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104 cfu/mL) diets plated in Tryptic
Soy Agar (TSA) and De Man, Rogosa and Sharpe (MRS) at 37ºC during 72 h. Values are
least square means ± SE. *P ≤ 0.05; **P ≤ 0.01. DNA amplification by PCR of strains of
Bacillus amyloliquefaciens, Pediococcus pentocaceus, Lactobacillus plantarum and
Pediococcus acidilactici in the 4 experiemntal diets. Amplification by PCR of probiotic
strains in proximal jejunum (PJ), distal ileum (DI), cecum, colon and rectum of pigs (A).
Potential mechanism for probiotic dysregulation of autophagy and increase in serum
concentrations of 8-h post feeding insulin in liver of pigs fed control + probiotics (CONP; 6.2 × 104 cfu/mL) and high-fructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104
cfu/mL) (B). Averages serum levels of insulin, glucose, homeostatic model assessment
(HOMA), leptin, interleukin 1α (IL-1α), tumor necrosis factor alpha (TNFα), and
transforming growth factor beta (TGF-β) at 8-h post feeding (C), and representative
western blots and relative protein expression of protein kinase B (PKB Ser473),
ubiquitin-binding protein p62 (p62), microtubule-associated protein 1A/1B light chain 3A
(LC3 I/II), and extracellular signal-regulated kinase (ERK) in liver tissue and longissimus
dorsi (D) from pigs fed a control (CON-N), control + probiotics (CON-P; 6.2 × 104
cfu/mL), high-fructose high-fat 2 (HFF2-N), or high-fructose high-fat 2 + probiotics
(HFF2-P; 6.2 × 104 cfu/mL) diet during 10 weeks. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used to normalize p62 and ERK. Values are least square
means ± SE.
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Fig. 2.4 Gene expression analysis for reference genes, inflammation and fibrosis
genes, and transcription factor and enzyme genes. Average expression stability values
(M) of potential reference genes in liver cyclin-G-associated kinase (GAK), vacuolar
protein

sorting-associated

porphobilinogen

deaminase

protein

4A

(HMBS),

(VPS4A),

beta-2-microglobulin

glyceraldehyde-3-phosphate

(B2M),

dehydrogenase

(GAPDH), hypoxanthine-guanine phosphoribosyltransferase (HPRT1), and ribosomal
protein S18 (RPS18) plotted from least stable (left) to most stable (right). Pairwise
variation (Vn/Vn + 1) between the normalization factors NFn and NFn+1 to determine
the optimal number of reference genes for normalization (A).

Relative mRNA

abundance potential reference genes normalized by 3 most stable genes in liver tissue
(VPS4A, GAK and HMBS) (B). Relative mRNA abundance of tumor necrosis factor
alpha (TNFα), transforming growth factor beta (TGF-β), interleukin 1α (IL-1α),
interleukin 1β (IL-1β), toll-like receptor 4 (TLR4) and smooth muscle alpha (α)-2 actin
(ACTA2) (C), sterol regulatory element-binding protein 1c (SREBP-1c), carbohydrateresponsive element-binding protein (ChREBP), liver X receptor alpha (LXR-α),
peroxisome

proliferator-activated

receptor

gamma

(PPARγ),

methionine

adenosyltransferase 1a (MAT1A), and phosphate cytidylyltransferase 1, choline, alpha
(PCYT1A) (D), and fatty acid synthase (FASN), acetyl-coa carboxylase alpha (ACACA),
acyl-CoA synthetase long-chain 1 (ACSL-1), fatty-acid-binding protein (FABP),
carnitine palmitoyltransferase 1 (CPT1), branched chain keto acid dehydrogenase E1,
alpha polypeptide (BCKDHA), and isocitrate dehydrogenase 2 (IDH2) (E) in liver tissue
from pigs fed a control (CON-N), control + probiotics (CON-P; 6.2 × 104 cfu/mL), high-
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fructose high-fat 2 (HFF2-N), or high-fructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104
cfu/mL) during 10 weeks. Values are least square means ± SE.
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Fig. 2.5 One-carbon metabolism metabolomics results. One-carbon metabolism
metabolic pathways in the liver, and relevant metabolites. Red and blue arrows represent
relative increase and decrease in concentration of metabolite in pigs fed HFF2 compared
to CON, respectively (A). Fold change in HFF2 compared to CON, and heat map
representing the changes in metabolites pertaining to bile acids, β-oxidation, one-carbon
metabolism, and nucleic acids. Each row shows data for a specific metabolite, and each
column shows data from liver or plasma in pigs fed a control (CON-N), control +
probiotics (CON-P; 6.2 × 104 cfu/mL), high-fructose high-fat 2 (HFF2-N), or highfructose high-fat 2 + probiotics (HFF2-P; 6.2 × 104 cfu/mL) during 10 weeks (B). Blue
and red represent the row minimum and maximum, respectively.
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Fig. 2.6. Tricarboxylic acid cycle (TCA) and urea cycle metabolomic and serum
results. Tricarboxylic acid cycle (TCA), urea cycle, and related metabolic pathways, and
relevant metabolites. Red and blue arrows represent relative increase and decrease in
concentration of metabolite in pigs fed HFF2 compared to CON, respectively (A). Fold
change in HFF2 compared to CON, heat map representing the changes in metabolites
pertaining to the TCA cycle, the urea cycle, and amino acids, and average serum levels of
bilirubin, blood urea nitrogen (BUN), total protein, and albumin on d 40 and d 65 at 2-h
post feeding (B) in pigs fed a control (CON-N), control + probiotics (CON-P; 6.2 × 104
cfu/mL), high-fructose high-fat 2 (HFF2-N), or high-fructose high-fat 2 + probiotics
(HFF2-P; 6.2 × 104 cfu/mL) during 10 weeks (B). Each row shows data for a specific
metabolite, and each column shows data from liver Blue and red represent the row
minimum and maximum, respectively.

60

61

Fig. 2.7. Lipid metabolism metabolomic and serum results. Fold change in HFF2
compared to CON and heat map representing the changes in phosphatidyl cholines (PC),
lysophosphatidyl

cholines

(LPC),

phosphatidylethanolamine

(PE),

lysophosphoethanolamines (LPE), cholesteryl esters (CE), sphingomyelins (SM),
diacylglycerols (DAG), and triacylglycerides (TAG) in liver and plasma (A), and average
serum levels of low-density lipoproteins (LDL), high-density lipoproteins (HDL),
cholesterol, non-sterified fatty acids (NEFA), and triacylglycerides (TAG) on d 40 and d
65 at 2-h post feeding in pigs fed a control (CON-N), control + probiotics (CON-P; 6.2 ×
104 cfu/mL), high-fructose high-fat 2 (HFF2-N), or high-fructose high-fat 2 + probiotics
(HFF2-P; 6.2 × 104 cfu/mL) during 10 weeks (B). Each row shows data for a specific
metabolite, and each column shows data from liver or plasma. Blue and red represent the
row minimum and maximum, respectively. Values are least square means ± SE.
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3. CONCLUSION
The primary objective of this thesis was to develop a diet-induced, pediatric
model of NAFLD in neonatal Iberian pigs by the controlled administration of a Western
diet, and to investigate the molecular mechanisms underlying the pathogenesis of the
disease, as well as their interactions with each other. Based on the serum biochemistry
and histological analysis, we conclude that we successfully developed the first large
animal model of pediatric NAFLD in neonatal pigs. Upon this development, we revealed
that related metabolic disorders, such as obesity and insulin resistance, are not necessary
for the development of NAFLD. In addition, unlike other swine models, we were able to
develop NASH in only 10 weeks, allowing us to remain in the juvenile time period. The
metabolomics elucidated several molecular pathways that may contributed to the
pathogenesis of NAFLD: 1) dysregulation of one carbon metabolism, which may have
impaired the export of fat out of the liver, and 2) dysregulation the TCA and urea cycles
in the mitochondria, which may have led to a decrease in BUN, and hence ammonia
excretion, as well as accumulation of amino acids in liver and blood.
The second objective of this thesis was to determine if supplementation of a
commercial probiotic mixture of Lactobacillus plantarum, Pediococcus acidilactici,
Pediococcus pentosaceus, and Bacillus amyloliquefaciens in a HFF diet will prevent the
development of NAFLD. Contrary to our hypothesis, no probiotic effect was seen in any
of the clinical parameters of NAFLD. In fact, relative liver weight, histological
parameters such as Mallory-Denk bodies and hepatic ballooning were significantly more
severe in HFF2-P compared to HFF2-N. In addition, Western blot analysis demonstrated
that probiotic supplementation led to the dysregulation of autophagy, regardless of diet,
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as well as increased insulin levels. Further research is needed to explore the mechanisms
that lead to this dysregulation and to assess whether this effect is strain specific or spread
out among all the commercial probiotics.
In summary the results of this study represents a novel large animal model of
pediatric NAFLD which can potentially be used to further investigate the pathogenesis
and etiology of NAFLD.
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APPENDIX
Table A.1: Feed intake, body weight (BW) on d 0 and 70, average daily gain (ADG),
relative liver weight and fasting leptin on d 70 in piglets fed either control (CON-N) or
high-fructose high-fat 1 (HFF1-N) during 10 weeks. Values are least square means ± SE.
P ≤ 0.01.

c,d

Item
Nº (pen)
M/F
Feed intake, L∙kg BW-1·day-1
BW d0, kg
BW d70, kg
ADG, g∙d-1
Relative liver weight, g∙kg BW-1
Leptin, ng∙mL-1

CON-N
8 (4)
4/4
0.18
3.69 ± 0.26
22.3 ± 0.70
0.27 ± 0.01
31.1c ± 1.28
5.56 ± 0.71
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HFF1-N
5 (2)
3/2
0.18
3.92 ± 0.35
23.7 ± 0.89
0.28 ± 0.01
38.0d ± 1.74
6.86 ± 0.92

Table A.2: Target and reference gene primer information for quantitative PCR (qPCR)
assays.
Accession
Number1

Gene

Protein

Primer Sequence

F: CAGAGCTAGGCTAGGAGGAATA
R: ATCCAGGTTTGCAGGATCAG
Long-chain-fatty-acid-CoA ligase F: GAACAGGGTTGCTTTGCTTATT
1
R: GAGTTCGCCTTTGTTGATGATG
Long-chain-fatty-acid-CoA ligase F: CAGAATACCTGGGCTCCTTTC
5
R: GATGATCCACTCTGGCCTATTC
F:GGGAGAAGATGACCCAGATTATG
Actin, aortic smooth muscle
R:TACGTCCAGAGGCGTAGAG
F:CCACACTGAGTTCACTCCTAAC
Beta-2-microglobulin
R:GGTCTCGATCCCACTTAACTATC
Carbohydrate-responsive element- F:ACTCAACGCTGCCATCAA
binding protein
R:ATGCTGAACACCCAGAACTT
F: CTCCCTCCAAAGGAACTGATTG
Claudin-2
R:GGACTGTGGGATGGCTTTATT
F:ACAGTGGTTCAGTTGGAAGG
Fatty acid-binding protein
R:CAGTGTCATGGTACTGGTGATTA
F:AGCTCAGGAAGGTGATCCT
Fatty acid synthase
R:AGGTTGTTGACGCTGTACTC
F:AATCGCAGTGATGTCCTTCC
Cyclin-G-associated kinase
R:GCTTCGAGTCCAGAAACAGC
Glyceraldehyde-3-phosphate
F:ACCTCCACTACATGGTCTACA
dehydrogenase
R:ATGACAAGCTTCCCGTTCTC
F:GCAACGCTGAAAGCCTTATAC
Porphobilinogen deaminase
R:CAGGCTCTTCTCTCCAATCTTAG
Hypoxanthine-guanine
F:AATTATGGACAGGACTGAACGG
phosphoribosyltransferase
R:CAGCAGGTCAGCAAAGAATTTATAG
F:CCTGGATGAGGCAGTGAAAT
Interleukin-1 alpha
R:CAGTCGGGTTTCTGAGATTCTT
F:AATCTGGGTTCAATCAGGAGAC
Interleukin 1β
R:CAGCCTCGACATTTCCCTTAT
F:TGAAGCTCCACCACCAAAG
Mitogen-activated protein kinase 8
R:GTTCTCTCCTCCAAGTCCATAAC
F:GCGATTGAGGTGATGCTTCT
Oxysterols receptor LXR-alpha
R:TTGGCAAAGTCTTCCCGATTAT
F:GCAGGAAAGTCTAGGAGATCAG
Occludin
R:GGATATTCCCTGATCCAGTCTTC
Peroxisome proliferator-activated F:CTCCACACTATGAAGACATCCC
receptor gamma
R:CACTTTGATGGCACTTTGGTAG
F:GGATGAGGTGGAACGTGTAATC
Ribosomal protein S18
R:CTTCCCATCCTTCACATCCTTC
Sterol regulatory element-binding F:GACTACATCCGCTTCCTTCAG
protein 1
R: GGTCCTTCAGAGACTTGCTTT
F:CACGTGGAGCTATACCAGAAAT
Transforming growth factor beta-1
R:ACATCAAAGGACAGCCACTC
F: CGTGCAGGTGGTTCCTAA
Toll-like receptor 4
R:AGTTAAAGCTCAGGTCCAGTATC
F:CCTACTGCACTTCGAGGTTATC
Tumor necrosis factor alpha
R: GAGACGATGATCTGAGTCCTTG
Vacuolar protein sortingF:CAAAGCCAAGGAGAGCATTC
associated protein 4A
R:ATGTTGGGCTTCTCCATCAC

Band
Size

XM_021066227.1 ACACA Acetyl-CoA carboxylase 1

94

XM_005671709.3 ACSL1

96

XM_013990488.2 ACSL5
XM_013983522.2 ACTA2
XM_021096362.1 B2M
XM_013995540.2 ChREBP
XM_021079578.1 CLDN2
NM_001004046.2 FABP1
NM_001099930.1 FASN
XM_021100830.1 GAK
KJ786424.1

GAPDH

XM_021102144.1 HMBS
XM_021079503.1 HPRT1
XM_005655198.3 IL-1A
JQ839263.1

IL-1B

XM_001929166.6 JNK1
XM_021081446.1 LXRa
XM_005672522.3 OCLN
XM_005669784.3 PPARG
XR_001298240.2 RPS18
XM_021066226.1 SREBP
XM_021093503.1 TGFβ1
NM_001113039.2 TLR4
JF831365.1

TNFα

XM_021093432.1 VSPS4A

87

98
96
97
149
128
105
126
88
90
110
114
96
119
111
118
103
101
99
97
101
106
97
221

Table A.3: Primer information for DNA amplification by PCR of strains of Pediococcus
acidilactici, Pediococcus pentocaceus, Bacillus amyloliquefaciens and Lactobacillus
plantarum supplemented in the diet.

Bacteria

Primer Sequence

Region

F: TCTCGCCGATTGAATATC

1695-1712

R: TAGGTCCCGCAATTTAAG

1823-1840

F: TCACTCTTTACGCCCTTC

1073-1090

R: GCGGGAGCATTACTATTT

1254-1271

F: CCAACATATAAGACCTCTAC

283-302

R: TTATTTCATCCCATCCTGAC

519-538

F: AAATCGTGATCCATTGCC

117022-117040

R: CTACTTTTTAGATCAGCCC

117159-117176

Pediococcus acidilactici

146

Pediococcus pentocaceus

Bacillus amyloliquefaciens

Lactobacillus plantarum

Band Size

199

88

256

164

Relative mRNA abundance

CON-N

5.2

P = 0.71

HFF1-N
P = 0.36

P = 0.017

P = 0.30

P = 0.32

5
4.8
4.6

4.4
4.2
4

TGFβ

TNFα

IL-1α

TLR4

ACTA2

Fig. A.1 Relative mRNA abundance of inflammatory factors. Relative mRNA
abundance of tumor necrosis factor alpha (TNFα), transforming growth factor beta (TGFβ), interleukin 1α (IL-1α), toll-like receptor 4 (TLR4) and smooth muscle alpha (α)-2
actin (ACTA2) in liver tissue from pigs fed a Control (CON-N), Control + probiotics
(CON-P; 6.2 × 104 cfu/mL), High-fructose high-fat (HFF2-N), or High-fructose high-fat
+ probiotics (HFF2-P; 6.2 × 104 cfu/mL) during 10 weeks. Values are least square means
± SE.
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